

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Smoking is the first leading cause of Cardiovascular Disease in Young Men: The Korean Life Course Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024453
Article Type:	Research
Date Submitted by the Author:	06-Jun-2018
Complete List of Authors:	Jee, Yongho; Seoul National University, Department of Public Health Jung, Keum Ji; Yonsei University Graduate School Institute for Health Promotion, Dept. of Public Health Lee, Sunmi; National Health Insurance Service, Health Insurance Policy Research Institute Back, Joung Hwan; Health Insurance Policy Research Institute Jee, Sun Ha; Graduate School of Public Health, Yonsei University, Epidemiology Cho, Sung-il ; Seoul National University, Department of Public Health
Keywords:	Smoking, Cardiovascular Disease, Young adults

SCHOLARONE™
Manuscripts

Peer Review Only

Smoking is the first leading cause of Cardiovascular Disease in Young Men:

The Korean Life Course Health Study

Yongho Jee, MPH^{1,2}, Keum Ji Jung, PhD^{2,4}, Sunmi Lee, PhD³, Joung Hwan Back, PhD³,
Sun Ha Jee, PhD^{2,4*}, Sung-il Cho, MD, PhD^{1*}

¹ Department of Public Health, Seoul National University, Seoul, Republic of Korea

² Institute for Health Promotion, Graduate School of Public Health, Yonsei University,
Seoul, Republic of Korea

³ Health Insurance Policy Research Institute, Wonju, Republic of Korea

⁴ Department of Epidemiology and Health Promotion, Graduate School of Public Health,
Yonsei University, Seoul, Republic of Korea

Running title: Smoking is the first leading cause of Cardiovascular Disease

*These last authors contributed equally to this work

*Corresponding authors. Department of Epidemiology and Health Promotion, Graduate
School of Public Health, Yonsei University, Seoul, Republic of Korea.

E-mail address: jsunha@yuhs.ac (S.H. Jee).

Department of Public Health, Seoul National University, Seoul, Republic of Korea

1
2
3
4 E-mail address: scho@snu.ac.kr (S.I. Cho).
5

6 These two authors equally contributed as corresponding author.
7
8
9

10 Word count: 3828
11

12 Table 3, Figure 4
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

For peer review only

Abstract

Objective: To examine the effect of smoking on risk of atherosclerotic cardiovascular disease (ASCVD) in Korean young adults and to examine whether serum total cholesterol levels could modify the effect of smoking on ASCVD.

Design: A prospective cohort study within a national insurance system.

Setting: Health screenings provided by national insurance in 1992 and 1994.

Participants: 118,531 young men between 20 and 29 years of age and were followed up for 23 years.

Outcome measure: To assess the independent effects of smoking on the risk of Ischemic Heart Disease (IHD), stroke, and ASCVD, Cox proportional hazards regression models were used, controlling for age, hypertension, diabetes, hypercholesterolemia, and alcohol drinking.

Results: The total number of current smokers was 78,455 (66.2%), and 94,113 (79.7%) of the sample recorded a total cholesterol level < 200 mg/dl measured at baseline. Between 1993 and 2015, 2,786 cases of IHD (53/100,000 person year), 2,368 cases of stroke (45.4/100,000 person year), and 6,368 ASCVD (122.7/100,000 person year) occurred. The risk of IHD, stroke, and total ASCVD events was found to increase for current smokers, with a hazard ratios (HR) with 95% Confidence Interval (CI) of 1.5 (95% CI: 1.3,1.6), 1.4 (95% CI: 1.2,1.6), and 1.4 (95% CI: 1.3,1.5), respectively. Further, the risks above were also found throughout the range of serum levels of cholesterol.

1
2
3
4 **Conclusions:** Smoking among Korean young adult men was independently associated
5
6 with increased risk of IHD, stroke and ASCVD. The concentration of cholesterol in
7
8 Korean men did not modify the effect of smoking on ASCVD.
9

10
11 **Keywords:** Smoking, Cardiovascular Disease, Young adults
12
13
14
15
16
17
18
19
20
21

22 **Strengths and limitations of this study**

23

- 24
25 • Novel result from Korean young adults is that smoking is the first leading cause of
26
27 Cardiovascular Disease (CVD) while smoking is the second leading cause of CVD in
28
29 middle aged adults.
30
- 31
32 • The large sample size of cohort with 118,531 young men between 20 and 29 years of
33
34 age and were followed up for 23 years.
35
- 36
37 • The limitations of this study include possible measurement errors and the non-random
38
39 sample used.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

INTRODUCTION

Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death globally, with more people dying from ASCVD than any other causes of death annually. A total of 17.7 million people died as a result of ASCVDs in 2015 globally, comprising 31% of all deaths. Of these deaths, 7.4 million are estimated to have been the result of coronary heart disease, whilst 6.7 million were due to stroke (WHO). According to previous studies published in the western countries, tobacco use has been reported to be a major risk factor for ASCVD following hypertension.¹

A growing concern is that for young adults, cigarette smoking may be the first leading cause of ASCVD, owing to the high prevalence of cigarette smoking in comparison to lower levels of alternate risk factors, including hypertension, diabetes, and high cholesterol levels. However, despite these observations, there remain only a small number of studies considering the relationship between smoking and ASCVD in Korea and other countries in East Asia.²⁻⁵

Further, comparisons with Western populations may be less informative owing to the relatively lower levels of cholesterol commonly present in Asian countries. Biological studies have explored the interaction between smoking and serum cholesterol levels.⁶⁻⁹ Nevertheless, very few studies have analyzed the interaction effects of smoking and serum cholesterol on ASCVD in young adults

‘World No Tobacco Day 2018’ is a campaign, with the primary objective of raising awareness of the link between tobacco use and negative health outcomes, predominantly heart and other cardiovascular diseases (CVD) including stroke. It will

1
2
3
4 also seek to expand the range of potential strategies key public actors such as
5
6 governmental and public bodies can take to reduce the health risks of tobacco use. If
7
8 there is an established link between tobacco smoking in young adults and CVD, the
9
10 campaign will further increase awareness on smoking in young adults. The government
11
12 and the public can then subsequently take actions to reduce risks of smoking at earlier
13
14 stage. Unfortunately, however, the association between smoking and CVD in young
15
16 adults has not received much attention because at least a long term (over 20 years)
17
18 follow-up study is needed. This serves as motivation for this study, in which we aimed
19
20 to examine the effect of smoking on risk of ASCVD in Korean young adults with
21
22 relatively low serum cholesterol levels. We also investigated whether the effect of
23
24 smoking can be modified by serum levels of cholesterol.
25
26
27
28
29
30

31 **METHOD**

32 **Study participants**

33
34
35
36 In Korea, the Korean Medical Insurance Corporation (KMIC) provided health insurance
37
38 for private school staff and civil servants prior to the current insurance system, under
39
40 which it was integrated as National Health Insurance.² A total of 4,862,438 (10.7%) of
41
42 the Korean population were covered by KMIC insurance, of which 1,297,833 were
43
44 employees, and 3,364,605 were dependents. All insured participants are required to
45
46 participate in a biennial health checkup.² Approximately 94% of the insured participants
47
48 in 1992 and 1994 were examined biennially. We established a prospective cohort for
49
50 participants (aged 20-29) who routinely responded to the questionnaire on disease risk
51
52
53
54

1
2
3
4 factors and chronic diseases, naming this study the Korean Life Course Health Study
5 (KLCHS). The KLCHS cohort included 307,041 Koreans (142,461 males, 164,580
6 females) who were screened by KMIC in 1992 and 1994. Of these participants, 205,840
7 (67.0%) were registered in 1992 and 101,201 (33.0%) were registered in 1994.
8
9

10
11
12
13 Of these 307,041 participants, 71,760 (23.4%) who had incomplete data height, blood
14 pressure, fasting glucose, total cholesterol, or body mass index were excluded. We also
15 excluded 6,170 people from our analysis who reported a past history of cancer and
16 ASCVD, as well as 2,091 people who had missing information on smoking, exercise, or
17 alcohol drinking, and 65 people who died before start of follow-up. Female participants
18 were excluded, because of the low prevalence of smoking for females in Korea,
19 resulting in a total of 118,531 eligible participants for the analysis (Figure 1). The study
20 proposal obtained an approval by the Institutional Review Board of Human Research,
21 Yonsei University (4-2001-0029). This study was a retrospective cohort using past
22 routine laboratory data and did not receive consent.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40
41 The biennial KMIC screening was provided at local hospitals by medical practitioners
42 according to standard protocols. During the two-year interval examination from 1992 to
43 2008, we examined the variables related to the lifestyle of participants, such as daily
44 smoking amount, duration of smoking, and variables related to drinking. From data
45 collected at baseline, participants were defined as 'current smokers' if they were
46 smoking currently, 'never smokers' if they had no prior history of smoking, and 'ex-
47
48
49
50
51
52
53
54

1
2
3
4 smokers' if they had previously smoked but at the time of measurement did not smoke.
5
6 Current smokers were further categorized by amount of cigarettes consumed on average
7
8 per day (1–9, 10–19, and 20 or greater) as well as duration of smoking (1–9, 10–19, and
9
10 20 or more years) following the example of previous studies.^{2,10,11}
11

12
13 The definition of hypertension was a systolic BP \geq 140 mmHg or diastolic BP \geq 90
14
15 mmHg.¹² Body mass index (BMI) was measured as weight (kg) / height (m)². Serum
16
17 total cholesterol was grouped as desirable (<200 mg/dl), borderline-high (200-239
18
19 mg/dl), and high (\geq 240 mg/dl).¹³ Definition of diabetes was fasting blood glucose \geq
20
21 126 mg / dl.¹⁴
22
23
24
25
26
27
28

29 **Follow-up and outcomes**

30
31
32 The main outcome variables used in the analysis were morbidity and mortality
33
34 categorized by IHD, stroke, and ASCVD. For IHD, alone (ICD 10 codes, I20–I25),
35
36 acute myocardial infarction (AMI) alone (I21), and angina pectoris (AP) alone (ICD 10
37
38 codes, I20) are used. For stroke, stroke alone (I60-I69) was used. Finally, with regard to
39
40 ASCVD, we used total ASCVD, including disease of hypertensive (I10–I15), ischemic
41
42 heart disease (I20–I25), all stroke (I60–I69), other heart disease (I44–I51), sudden death
43
44 (R96), and other vascular disease (I70–I74).
45
46

47
48 The study outcomes were identified through diagnosis information recorded in hospital
49
50 admission, and from causes of death using death certificates. The study follow-up was
51
52 nearly 100% complete, as we were able to search ASCVD event data electronically by
53
54

1
2
3
4 KMIC registrants regarding the morbidity information of ASCVD. The period of
5
6 follow-up was 23 years from January 1st, 1993 to December 31st, 2015. Data on causes
7
8 of death were available during years 1993–2015, and incidence could be tracked during
9
10 years 1995–2015.

11
12
13 A validation study was conducted by 20 internists from the Korean Society of
14
15 Cardiology in 2009.¹⁵ For the participants who provided written permission for the use
16
17 of their personal information, 673 CHD events between 1994 and 2007 were confirmed
18
19 with individual hospital medical records, showing that 73% of designated myocardial
20
21 infarctions were valid. The validation study was updated in 2013 with a value of 93%.¹⁶
22
23
24 The validation study on mortality data has not been conducted.

30 **Statistical analysis**

31
32
33 First, we examined relationships between smoking status and established ASCVD risk
34
35 factors at baseline. In considering continuous ASCVD risk factors, we used ordinary
36
37 least squares regression and coded smoking quantity as an ordinal variable. In this study,
38
39 the Mantel Haenszel method was applied for dichotomous variables.¹⁷

40
41
42 To assess the independent effects of smoking on the risk of IHD, stroke, and ASCVD,
43
44 Cox proportional hazards models were used, controlling for age and the confounding
45
46 variables such as hypertension, diabetes, high cholesterol, and alcohol drinking. The
47
48 proportional assumption was also tested utilizing Schoenfeld residuals, and the survival
49
50 curve according to smoking status was plotted using the life-table method. We used
51
52 Levins formula for calculating population attributable risk (PAR).¹⁸ In additional

1
2
3
4 analyses, we excluded all events that had occurred in the first 4 years of follow-up.
5
6 These analyses ensured sensitivity in our results. In all analyses, a two-sided
7
8 significance level of 0.05 was used.
9

14 **Patient and Public Involvement**

15
16
17 Patients and or public were not involved.
18
19
20
21
22
23

24 **RESULTS**

25
26 The average age of the study participants was 26.7 ± 2.0 (SD) years. Among the
27
28 118,531 men, 78,455 (66.2%) were current smokers, 15,126 (12.8%) were ex-smokers,
29
30 and 92,403 (78%) had hypertension. For total cholesterol, 94,413 (79.7%) had a total
31
32 serum cholesterol level < 200 mg/dL, 19,764 (16.6%) had a borderline level of 200-240
33
34 mg/dL, and 4,444 (3.8%) had a level of 240 mg/dL or higher. In terms of amount of
35
36 smoking, 28.9% smoked more than 20 cigarettes per day while 45.5% and 25.6% of
37
38 current smokers smoked 1 to 9 and 10 to 19 cigarettes per day, respectively. Among
39
40 current smokers, 92.0% smoked for less than 10 years while 7.6% and 0.4% of current
41
42 smokers smoked for 10 to 19 years and more than 20 years, respectively.
43
44
45

46
47 Population characteristics by smoking status are presented in Table 1. After adjusting
48
49 for age, current smokers had a significantly higher body mass index (P for trend =
50
51 0.0056), higher consumption of alcohol drinking (P for trend $< .0001$), and higher
52
53 prevalence of diabetes (P for trend = 0.0060) than nonsmokers.
54

1
2
3
4 During 23 years of follow up (5,191,823 person-years), 2,786 (90 fatal) IHD cases
5 (53/100,000 person year), stroke cases 2,368 (126 fatal) (45.4/100,000 person year),
6 and 6,368 ASCVD cases (306 fatal) (122.7/100,000 person year) occurred
7
8
9

10
11 The independent effects of smoking on IHD, stroke, and ASCVD were analyzed
12 controlling for confounding factors through Cox proportional hazards models, as shown
13 in Table 2. The hazard ratios (HR) relating to IHD for current smokers were 1.5 (P
14 <.0001), and those of ex-smokers were 1.0 (P <.0001). The HR of stroke was 1.4 (P
15 <.0001) for current smokers and 1.1 (P = 0.5008) on ex-smokers.
16
17
18
19
20
21

22
23 Compared to nonsmokers, the HR for any ASCVD event was 1.4 (P < 0.0001) in
24 current smokers and 1.1 in ex-smokers (P = 0.1406). Figure 2 shows the survival
25 probability by smoking history (never, former, 1-9, 10-19, ≥20 cigarette per day among
26 current smokers) and the corresponding unadjusted association with ASCVD. The
27 overall results demonstrated that smoking among young men increased the risk for
28 ASCVD relative to nonsmokers. After adjusting for age and traditional ASCVD risk
29 factors, the HRs for IHD and stroke were estimated for groups classified by amount of
30 smoking (A and B in Figure 3) and duration of smoking (C and D in Figure 3). For IHD
31 and stroke, the risk of events increased linearly with higher amount of cigarette per day
32 (P for trend, <.0001 and <.0001, respectively) and longer duration of smoking (P for
33 trend, <.0001 and <.0001, respectively).
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 To examine whether serum total cholesterol levels could modify the effect of smoking
49 on ASCVD, we divided the cohort participants into quartile of total cholesterol. The
50 risks above were also found throughout the range of serum levels of cholesterol
51
52
53
54

1
2
3
4 demonstrating that serum total cholesterol levels did not modify the effect of smoking
5
6 on ASCVD (Figure 4).
7

8
9 Estimated risk factor prevalence in current studies of smoking and other additional risk
10
11 factors were used to estimate the PARs for IHD alone, stroke alone and total ASCVD
12
13 (Table 3). For IHD, current smoking accounts for about 24.9% of events, and
14
15 hypertension accounts for 8.1% of events. In the case of stroke, smoking was estimated
16
17 to account for 20.9%, whilst hypertension was estimated to be responsible for 13.3% of
18
19 stroke cases.
20
21

22 23 24 25 **DISCUSSION**

26
27 Our study investigated the association between smoking and risk of ASCVD among
28
29 Korean young men within a cohort study with a 23 year of follow-up. To our
30
31 knowledge, this is the first study focusing on Korean young adults. In our study,
32
33 smoking was the most crucial risk factor attributing to 20% of ASCVD mortality in
34
35 middle age.
36
37

38
39 Diabetes, hypertension, and hyperlipidemia are well known risk factors for ASCVD¹⁰.
40
41 However, for young adults with relatively low incidence of diabetes, hypertension and
42
43 hyperlipidemia, smoking is the most important and an independent risk factor for
44
45 predicting ASCVD in the present study. Furthermore, the high smoking rate among
46
47 young people is important with respect to the development of middle-aged hypertension
48
49 and transition to ASCVD.¹⁹⁻²⁰ Thus, middle-aged ASCVD morbidity is likely
50
51 predominantly predicted by smoking in young adulthood.
52
53

1
2
3
4 The body of research centered upon the health effects of smoking is steadily increasing,
5
6 with findings reported from many countries around the world. However, few studies
7
8 have examined the effect of smoking on ASCVD in young adults.²¹ Here, we present
9
10 evidence that current smoking is an independent risk factor affecting the incidence of
11
12 IHD, stroke and ASCVD.
13

14
15 These risk associations have been estimated across total serum cholesterol groups. A
16
17 cohort study in Hasayama Japan found that smoking showed positive association with
18
19 coronary heart disease in people with high levels of serum cholesterol above 180 mg /
20
21 dl, but not with people with low level of cholesterol less than 180 mg / dl].²²⁻²³
22
23 Afterward, six epidemiological studies were conducted. Among them, one study from
24
25 Puerto Rico Heart Health Program²⁴ showed similar results, but not all.⁷⁻¹¹ Of course,
26
27 all studies were conducted among adult populations. To the best of our knowledge, no
28
29 study has been done on young adults with much lower levels of serum cholesterol. In
30
31 addition, the high smoking rate among young adults is likely to be, even directly, linked
32
33 to high blood pressure among the adult population who developed ASCVD as a major
34
35 health problem.
36
37

38
39
40 In our analysis, there was no observed increase in risk of IHD or stroke among ex-
41
42 smokers. That is, the risk of ASCVD in ex-smokers was similar with that of
43
44 nonsmokers. These findings suggest that the risk of IHD lasts for an unknown period,
45
46 while the high risk for ASCVD decreases after smoking cessation.
47
48

49
50 There are several studies regarding cardiovascular risk among young people. According
51
52 to a study conducted by Bernaards et al.,²⁵ blood pressure and waist circumference were
53
54

1
2
3
4 decreased by lowering weekly tobacco consumption in younger participants. However,
5
6 they did not report the risk of developing cardiovascular disease events due to changes
7
8 in smoking. This seems to be another significant topic relating to the health of young
9
10 adults. Another study conducted by Morotti et al.²¹ on young women with polycystic
11
12 ovary syndrome (PCOS) reported an association between smoking habitude in lean
13
14 PCOS patients, and the increase of soft markers of cardiovascular risk. For young adult
15
16 African Americans, the association between cigarette smoking and carotid intima
17
18 assuming the genetic variation of smokers was reported and the -930^{A/G} polymorphism
19
20 modified the association among young healthy adults.²⁶ The study on association
21
22 between second hand smoking among childhood and cardiovascular event in adulthood
23
24 was conducted and found that the carotid plaque risk in adulthood is increased in
25
26 children whose parents had smoked.²⁷⁻²⁸
27
28

29
30 This LCHS study has several strengths, such as high follow-up rates and a large,
31
32 national sample. The large sample size of cohort allowed us to investigate the
33
34 association of smoking with various levels of serum cholesterol. However, selection
35
36 bias may be a potential issue, since the final sample contains a subset of over 118,531
37
38 young male adults (38.6%) out of 307,041 subjects initially selected for our study. We
39
40 therefore urge conservative interpretations of our study results with regard to the
41
42 general population.
43
44

45
46 In conclusion, smoking is a leading cause of ASCVD among young adults in Korea, a
47
48 country with a low total cholesterol level and a high smoking rate. And the association
49
50 was not modified by total cholesterol level. Smoking among Korean young adult men
51
52 was independently associated with increased risk of IHD, stroke and ASCVD. The
53
54

1
2
3
4 concentration of cholesterol in Korean men did not modify the effect of smoking on
5
6 ASCVD. Therefore, smoking cessation on young adult smokers is essential to prevent
7
8 CVD later in adult life. Moreover, clinical practice guidelines and policies should
9
10 emphasize to treat nicotine addiction in young smokers.
11
12
13
14
15

16 **Acknowledgments:** We appreciate the assistance of the Korean National Health
17
18 Insurance Service, which provided the data for this study.
19
20
21
22
23

24 **Contributors:** Data analysis was undertaken by YJ and KJJ. The article was drafted by
25
26 YJ. SL, JHB, SHJ, and SC substantially contributed to the conception or design of the
27
28 work, revising the work, approved the final version to be published, and agreed to be
29
30 accountable for all aspects of the work in ensuring that questions related to the accuracy
31
32 or integrity of any part of the work are appropriately investigated and resolved.
33
34
35
36
37
38

39 **Funding Sources:** This study was funded with a grant from the Korean Health
40
41 Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
42
43 (HI14C2686). The funder had no role in the study design and data collection, in
44
45 analyzing and interpreting data, or in the decision to submit this work for publication
46
47
48
49

50 **Conflict of interests:** We declare that we have non conflicts of interest.
51
52
53
54

1
2
3
4 **Ethics approval:** The study proposal obtained an approval by the Institutional Review
5
6 Board of Human Research, Yonsei University (4-2001-0029).
7

8
9 **Provenance and peer review:** Not commissioned; externally peer reviewed.
10

11
12
13 **Data sharing statement:** No additional data are available.
14
15

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Updated May 2017. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Visited at 3 March, 2018.
2. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. *Cancer Causes Control*. 2004;15(4):341-8.
3. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. *JAMA* 1996: 1646–50.
4. Liu B-Q, Peto R, Chen Z-M, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. *Br Med J* 1998;317: 1411–22.
5. Niu S-R, Yang G-H, Chen Z-M, et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. *Br Med J* 1998;317: 1423–24.
6. Robertson TL, Kato H, Gordon T, Kagan A, Rhoads GG, Land CE, Worth RM, Belsky JL, Dock DS, Miyanishi M, Kawamoto S. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. *Am J Cardiol*. 1977;39(2):244-9. PubMed PMID: 835483.
7. Lawlor DA, Song YM, Sung J, Ebrahim S, Smith GD. The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study. *Stroke*.

2008;39(3):760-7. doi: 10.1161/STROKEAHA.107.494823. Epub 2008 Jan 31.

PubMed PMID: 18239177.

8. Hozawa A, Okamura T, Kadowaki T, Murakami Y, Nakamura K, Hayakawa T, Kita Y, Nakamura Y, Okayama A; Hirotsugu Ueshima for NIPPON DATA80 Research group.

Is weak association between cigarette smoking and cardiovascular disease mortality observed in Japan explained by low total cholesterol? NIPPON DATA80. *Int J Epidemiol.* 2007 Oct;36(5):1060-7. Epub 2007 Sep 10. PubMed PMID: 17846054.

9. Nakamura K, Barzi F, Huxley R, Lam TH, Suh I, Woo J, Kim HC, Feigin VL, Gu D,

Woodward M; Asia Pacific Cohort Studies Collaboration. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? *Heart.* 2009;95(11):909-16. doi:

10.1136/hrt.2008.147066. Epub 2009 Feb 5. PubMed PMID: 19196734.

10. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. *JAMA.* 1999;282(22):2149-55.

11. Jee SH, Park J, Jo I, Lee J, Yun S, Yun JE, Jang Y. Smoking and atherosclerotic cardiovascular disease in women with lower levels of serum cholesterol. *Atherosclerosis.* 2007;190(2):306-12. Epub 2006 May 4.

12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program

1
2
3
4 Coordinating Committee. The Seventh Report of the Joint National Committee on
5
6 Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7
7
8 report. *JAMA*. 2003;289(19):2560-72. Epub 2003 May 14. Erratum in: *JAMA*. 2003 Jul
9
10 9;290(2):197. PubMed PMID: 12748199.

11
12
13 13. The National Cholesterol Education Program. Report of the Expert Panel on Blood
14
15 Cholesterol Levels in Children and Adolescents. NIH Publication No. 91-2732.
16
17 Bethesda, MD; 1994.

18
19
20 14. National Diabetes Data Group. Report of the Expert Committee on the Diagnostic
21
22 Classification of Diabetes. *Diabetes Care*. 1997;20(7):1183–97.

23
24
25 15. Kimm H, Yun JE, Lee SH, et al. Validity of the diagnosis of acute myocardial
26
27 infarction in Korean national medical health insurance claims data: the Korean Heart
28
29 Study (1). *Korean Circ J* 2012;42:10–15.

30
31
32 16. Kim HY. Validity of the diagnosis of acute myocardial infarction in Korean national
33
34 medical health insurance claims data: the Korean Heart Study [Master thesis]. Yonsei
35
36 University, Seoul, Korea, June 2013.

37
38
39 17. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1: The analysis of
40
41 case-control studies. Lyon, France: IARC Scientific Publication No. 32, pp. 146–50.

42
43
44 18. Levin ML. The occurrence of lung cancer in man. *Acta Intern Cancer* 1953;19:531.

45
46
47 19. Thut AB, Blizzard L, Schmidt MD, Luc PH, Granger RH, Dwyer T. The association
48
49 between smoking and hypertension in a population-based sample of Vietnamese men. *J*
50
51 *Hypertens*. 2010; 28: 245 – 50.

- 1
2
3
4 20. Kim BJ, Seo DC, Kim BS, Kang JH. Relationship between cotinine-verified
5 smoking status and incidence of hypertension in 74,743 Korean adults. *Circ J*. 2018 Feb
6 28. doi: 10.1253/circj.CJ-17-1188. [Epub ahead of print].
7
8
9
10
11 21. Morotti E, Battaglia B, Fabbri R, Paradisi R, Venturoli S, Battaglia C. Cigarette
12 smoking and cardiovascular risk in young women with polycystic ovary syndrome. *Int*
13 *J Fertil Steril*. 2014;7(4):301-12. Epub 2013 Dec 22.
14
15
16
17
18 22. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the
19 general population in Japan. *J Hypertens* 1990;8(Suppl 5):S9–S15.
20
21
22
23 23. Fujishima M, Kiyohara Y, Ueda K, Hasuo Y, Kato I, Iwamoto H. Smoking as
24 cardiovascular risk factor in low cholesterol population: the Hisayama Study. *Clin Exp*
25 *Hypertens A*. 1992;14(1-2):99-108.
26
27
28
29
30
31 24. Gordon T, Garcia-Palmier MR, Kagan A, Kannel WB, Schiffman J. Differences in
32 coronary heart disease in Framingham, Honolulu and Puerto Rico. *J Chronic Dis*.
33 1974;27:329–44.
34
35
36
37
38 25. Bernaards CM1, Twisk JW, Snel J, van Mechelen W, Kemper HC. In a prospective
39 study in young people, associations between changes in smoking behavior and risk
40 factors for cardiovascular disease were complex. *J Clin Epidemiol*. 2005
41 Nov;58(11):1165-71.
42
43
44
45
46
47 26. Murtaugh KH, Borde-Perry WC, Campbell KL, Gidding SS, Falkner B. Obesity,
48 smoking, and multiple cardiovascular risk factors in young adult African Americans.
49
50
51
52
53
54

1
2
3
4 27. West HW, Juonala M, Gall SL, Kähönen M, Laitinen T, Taittonen L, Viikari JS,
5 aitakari OT, Magnussen CG. Exposure to parental smoking in childhood is associated
6 with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular
7 Risk in Young Finns Study. *Circulation*. 2015 Apr 7;131(14):1239-46. doi:
8 10.1161/CIRCULATIONAHA.114.013485. Epub 2015 Mar 23.
9

10
11
12
13
14
15 28. Roy MP, Steptoe A, Kirschbaum C. Association between smoking status and
16 cardiovascular and cortisol stress responsivity in healthy young men. *Int J Behav Med*.
17 1994;1(3):264-83.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Defining the study population

Figure 2. Survival of atherosclerotic cardiovascular disease event by smoking history in Korean young adult men, 1992-2015

Figure 3. Hazard ratios with 95% confidence intervals for from ischemic heart disease, and stroke by cigarette per day and duration of smoking

Figure 4. Hazard ratios with 95% confidence intervals for ischemic heart disease and stroke by total cholesterol groups of smokers compared with nonsmokers: Each group of total cholesterol levels are as follows: first, 149 mg/dl; second, 150-169 mg/dL; third, 170-194 mg/dL; fourth, ≥ 195 mg/dL. The reference group is non-smokers in each quartile of total cholesterol.

Table 1. Baseline Characteristics of the Korean Life Course Health Study, 1992-1994, According to Smoking Status*

Characteristic	Nonsmokers (n=24,950)	Ex-smokers (n=15,126)	No. of cigarettes per day among current smokers			P for Trend [¶]
			1-9 (n=22,642)	10-19 (n=35,690)	≥20 (n=20,123)	
Age, year	26.6 (2.1)	26.9 (1.9)	26.6 (2.0)	26.8 (1.9)	26.8 (1.9)	0.1622
Systolic Blood Pressure, mmHg	120.4 (11.6)	120.0 (11.8)	119.8 (11.6)	120.1 (11.6)	120.3 (11.6)	0.2558
Diastolic Blood Pressure mmHg	78.0 (9.0)	77.7 (9.1)	77.5 (9.0)	77.8 (9.0)	78.0 (9.0)	0.1122
Total cholesterol, mg/dL	173.4 (32.9)	173.4 (32.6)	172.9 (33.1)	174.5 (33.4)	177.2 (34.4)	0.9543
Body mass index, kg/m ²	22.3 (2.4)	22.4 (2.4)	22.3 (2.4)	22.5 (2.5)	22.9 (2.6)	0.0056
Fasting serum glucose, mg/dL	86.7 (13.3)	86.6 (13.5)	86.2 (14.1)	86.4 (14.1)	86.6 (15.3)	0.4821
Alcohol consumption, g per day	7.3 (17.7)	9.7 (19.7)	12.2 (22.6)	14.5 (25.1)	20.4 (36.1)	<.0001
Conditions, %						
Hypertension [†]	22.7	21.8	20.7	22.1	23.0	0.7987
Hypercholesterolemia [‡]	3.4	3.3	3.3	3.9	4.7	0.0743
Diabetes [§]	0.7	0.8	0.9	0.9	1.0	0.0060
Alcohol use	61.2	81.3	88.2	88.3	86.9	0.1035
Physical activity						

*Data are expressed as means (SD) unless otherwise indicated; †Systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least

1
2
3
4
5 90 mmHg; ‡Total cholesterol level of at least 6.21 mmol/L (240 mg/dL); § Fasting serum glucose value of at least 6.99 mmol/L (126 mg/L); || Consumption
6 of Soju which is a colorless distilled beverage of Korean origin; ¶Testing for trend across nonsmokers and current smokers; ex-smokers were excluded.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2. Risk of Morbidity from Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men in the Korean Life Course Health Study, 1992-2015*

Variables and Categories	Ischemic Heart Disease		Cerebrovascular Disease		Atherosclerotic Cardiovascular Disease	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age (5-year age group)	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.3 (1.2 – 1.4)	<.0001
Cigarette smoking						
Ex-smoker	1.0 (0.9 – 1.2)	0.8567	1.1 (0.9 – 1.3)	0.5008	1.1 (1.0 – 1.2)	0.1406
Current smoker	1.5 (1.3 – 1.6)	<.0001	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
Blood Pressure†						
High normal	1.2 (1.1 – 1.4)	<.0001	1.2 (1.0 – 1.3)	0.0152	1.2 (1.1 – 1.3)	<.0001
Stage 1 hypertension	1.6 (1.4 – 1.8)	<.0001	1.7 (1.5 – 2.0)	<.0001	1.7 (1.5 – 1.8)	<.0001
Stage 2 hypertension	2.0 (1.6 – 2.5)	<.0001	3.2 (2.5 – 4.0)	<.0001	2.9 (2.5 – 3.3)	<.0001
Total cholesterol‡						
Borderline-high cholesterol	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
High cholesterol	2.5 (2.1 – 2.8)	<.0001	1.7 (1.4 – 2.1)	<.0001	2.1 (1.8 – 2.3)	<.0001
Fasting blood sugar§						
Diabetes	1.3 (0.9 – 1.9)	0.1375	1.6 (1.1 – 2.3)	0.0222	1.5 (1.2 – 1.9)	0.0008
Physical activity						
No exercise	1.1 (1.0 – 1.3)	0.0122	1.1 (1.0 – 1.3)	0.2156	1.1 (1.0 – 1.3)	0.0075

*Hazard ratio (HRs) and 95% confidence intervals (CIs) from multivariable Cox proportional hazards models. †The reference category is normal (systolic

1
2
3
4
5 blood pressure<140 mmHg and diastolic blood pressure<90mm Hg). ‡ The reference category is desirable (serum cholesterol level, < 5.17 mmol/L [200
6 mg/dL]). §The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Table 3. Population Attributable Risks (PARs) and 95% Confidence Intervals (CIs) From Smoking and Other Risk Factors of Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men: The Korean Life Course Health Study

Variables and Categories	Prevalence %	Ischemic Heart Disease PAR (95% CI)	Cerebrovascular Disease PAR (95% CI)	Atherosclerotic Cardiovascular Disease PAR (95% CI)
Smoking				
Current smoker	66.2	24.9 (16.6 – 28.4)	20.9 (11.7 – 28.4)	20.9 (16.5 – 24.9)
Blood Pressure*				
Hypertension	22.0	8.1 (6.2 – 9.9)	13.3 (9.9 – 14.9)	9.9 (9.9 – 11.7)
Total cholesterol†				
Borderline	16.6	6.2 (4.7 – 9.1)	6.2 (4.7 – 7.7)	6.2 (4.7 – 7.6)
High	3.8	5.4 (4.0 – 6.4)	4.0 (2.9 – 4.7)	4.0 (2.9 – 4.7)
Fasting blood sugar‡				
Diabetes	0.9	0.3 (-0.9 – 0.8)	0.5 (0.08 – 1.1)	0.4 (0.2 – 0.8)
Physical activity				
No exercise	??			

*The reference category is normal (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90mm Hg). †The reference category is desirable (serum cholesterol level < 5.17 mmol/L [200 mg/dL]). ‡ The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).




Figure 1

64x56mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2

254x190mm (300 x 300 DPI)




Figure 3

254x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4

254x190mm (300 x 300 DPI)

Title: smoking is the first leading cause of cardiovascular disease in Young Men.

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation
Title and abstract	①	(a) Indicate the study's design with a commonly used term in the title or the abstract <i>Page 3</i> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <i>page 3</i>
Introduction		
Background/rationale	②	Explain the scientific background and rationale for the investigation being reported <i>page 5</i>
Objectives	③	State specific objectives, including any prespecified hypotheses <i>page 6, para 1.</i>
Methods		
Study design	④	Present key elements of study design early in the paper <i>Page 6, para 2</i>
Setting	⑤	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <i>page 6-7.</i>
Participants	⑥	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>page 6, page 8</i> (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	⑦	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <i>page 7, para 3, page 8</i>
Data sources/ measurement	⑧*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <i>page 6, page 7</i>
Bias	⑨	Describe any efforts to address potential sources of bias <i>page 14.</i>
Study size	⑩	Explain how the study size was arrived at <i>page 7</i>
Quantitative variables	⑪	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>page 8</i>
Statistical methods	⑫	(a) Describe all statistical methods, including those used to control for confounding <i>page 9</i> (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed <i>page 8</i> (e) Describe any sensitivity analyses <i>page 9-10</i>
Results		
Participants	⑬*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <i>page 10</i> (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram <i>page 7. (Figure 1)</i>
Descriptive data	⑭*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <i>page 10</i> (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) <i>page 10 (23 years of follow-up)</i>
Outcome data	⑮*	Report numbers of outcome events or summary measures over time <i>page 10.</i>
Main results	⑯	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <i>page 10, para 1 (Table 2)</i> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	page 11 (Figure 4)
2	Discussion			
3	Key results	18	Summarise key results with reference to study objectives	page 12 para 2
4	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 14, para 2.
5	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 14
6	Generalisability	21	Discuss the generalisability (external validity) of the study results	page 14
7	Other information			
8	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean Life Course Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024453.R1
Article Type:	Research
Date Submitted by the Author:	02-Oct-2018
Complete List of Authors:	Jee, Yongho; Seoul National University, Department of Public Health Jung, Keum Ji; Yonsei University Graduate School Institute for Health Promotion, Dept. of Public Health Lee, Sunmi; National Health Insurance Service, Health Insurance Policy Research Institute Back, Joung Hwan; Health Insurance Policy Research Institute Jee, Sun Ha; Graduate School of Public Health, Yonsei University, Epidemiology Cho, Sung-il ; Seoul National University, Department of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Smoking and tobacco, Public health, Cardiovascular medicine
Keywords:	Smoking, Cardiovascular Disease, Young adults

SCHOLARONE™
Manuscripts

Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean
Life Course Health Study

Yongho Jee, MPH^{1,2}, Keum Ji Jung, PhD^{2,4}, Sunmi Lee, PhD³, Joung Hwan Back, PhD³,
Sun Ha Jee, PhD^{2,4*}, Sung-il Cho, MD, PhD^{1*}

¹ Department of Public Health, Seoul National University, Seoul, Republic of Korea

² Institute for Health Promotion, Graduate School of Public Health, Yonsei University,
Seoul, Republic of Korea

³ Health Insurance Policy Research Institute, Wonju, Republic of Korea

⁴ Department of Epidemiology and Health Promotion, Graduate School of Public Health,
Yonsei University, Seoul, Republic of Korea

Running title: Smoking is the first leading cause of Cardiovascular Disease

*These last authors contributed equally to this work

*Corresponding authors. Department of Epidemiology and Health Promotion, Graduate
School of Public Health, Yonsei University, Seoul, Republic of Korea.

E-mail address: jsunha@yuhs.ac (S.H. Jee).

Department of Public Health, Seoul National University, Seoul, Republic of Korea

E-mail address: scho@snu.ac.kr (S.I. Cho).

1
2
3
4 These two authors equally contributed as corresponding author.
5
6
7

8 Word count: 3828
9

10 Table 3, Figure 4
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

For peer review only

Abstract

Objective: To examine the effect of smoking on risk of atherosclerotic cardiovascular disease (ASCVD) in Korean young men and to examine whether serum total cholesterol levels could modify the effect of smoking on ASCVD.

Design: A prospective cohort study within a national insurance system.

Setting: Health screenings provided by national insurance in 1992 and 1994.

Participants: 118,531 young men between 20 and 29 years of age and were followed up for 23 years.

Outcome measure: To assess the independent effects of smoking on the risk of Ischemic Heart Disease (IHD), stroke, and ASCVD, Cox proportional hazards regression models were used, controlling for age, hypertension, diabetes, hypercholesterolemia, and alcohol drinking.

Results: The total number of current smokers was 78,455 (66.2%), and 94,113 (79.7%) of the sample recorded a total cholesterol level < 200 mg/dl measured at baseline. Between 1993 and 2015, 2,786 cases of IHD (53/100,000 person year), 2,368 cases of stroke (45.4/100,000 person year), and 6,368 ASCVD (122.7/100,000 person year) occurred. The risk of IHD, stroke, and total ASCVD events was found to increase for current smokers, with a hazard ratios (HR) with 95% Confidence Interval (CI) of 1.5 (95% CI: 1.3,1.6), 1.4 (95% CI: 1.2,1.6), and 1.4 (95% CI: 1.3,1.5), respectively. Further, the risks above were also found throughout the range of serum levels of cholesterol.

1
2
3
4 **Conclusions:** Smoking among Korean young adult men was independently associated
5
6 with increased risk of IHD, stroke and ASCVD. The concentration of cholesterol in
7
8 Korean men did not modify the effect of smoking on ASCVD.
9

10
11 **Keywords:** Smoking, Cardiovascular Disease, Young adults
12
13
14
15
16
17
18
19
20
21

22 **Strengths and limitations of this study**

23

- 24
25 • Novel result from Korean young adults is that smoking is the first leading cause of
26
27 Cardiovascular Disease (CVD) while smoking is the second leading cause of CVD in
28
29 middle aged adults.
30
- 31
32 • The large sample size of cohort with 118,531 young men between 20 and 29 years of
33
34 age and were followed up for 23 years.
35
- 36
37 • The limitations of this study include possible measurement errors and the non-random
38
39 sample used.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

INTRODUCTION

Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death globally, with more people dying from ASCVD than any other causes of death annually. A total of 17.7 million people died as a result of ASCVDs in 2015 globally, comprising 31% of all deaths. Of these deaths, 7.4 million are estimated to have been the result of coronary heart disease, whilst 6.7 million were due to stroke¹. According to previous studies published in the western countries, tobacco use has been reported to be a major risk factor for ASCVD following hypertension.¹

A growing concern is that for young adults, cigarette smoking may be the first leading cause of ASCVD, owing to the high prevalence of cigarette smoking in comparison to lower levels of alternate risk factors, including hypertension, diabetes, and high cholesterol levels. However, despite these observations, there remain only a small number of studies considering the relationship between smoking and ASCVD in Korea and other countries in East Asia.²⁻⁵

Further, comparisons with Western populations may be less informative owing to the relatively lower levels of cholesterol commonly present in Asian countries. Biological studies have explored the interaction between smoking and serum cholesterol levels.⁶⁻⁹ Nevertheless, very few studies have analyzed the interaction effects of smoking and serum cholesterol on ASCVD in young adults

‘World No Tobacco Day 2018’ is a campaign, with the primary objective of raising awareness of the link between tobacco use and negative health outcomes, predominantly heart and other cardiovascular diseases (CVD) including stroke. It will

1
2
3
4 also seek to expand the range of potential strategies key public actors such as
5
6 governmental and public bodies can take to reduce the health risks of tobacco use. If
7
8 there is an established link between tobacco smoking in young adults and CVD, the
9
10 campaign will further increase awareness on smoking in young adults. The government
11
12 and the public can then subsequently take actions to reduce risks of smoking at earlier
13
14 stage. Unfortunately, however, the association between smoking and CVD in young
15
16 adults has not received much attention because at least a long term (over 20 years)
17
18 follow-up study is needed. This serves as motivation for this study, in which we aimed
19
20 to examine the effect of smoking on risk of ASCVD in Korean young adults with
21
22 relatively low serum cholesterol levels. We also investigated whether the effect of
23
24 smoking can be modified by serum levels of cholesterol.
25
26
27
28
29
30

31 **METHOD**

32 **Study participants**

33
34
35
36 In Korea, the Korean Medical Insurance Corporation (KMIC) provided health insurance
37
38 for private school staff and civil servants prior to the current insurance system, under
39
40 which it was integrated as National Health Insurance.² A total of 4,862,438 (10.7%) of
41
42 the Korean population were covered by KMIC insurance, of which 1,297,833 were
43
44 employees, and 3,364,605 were dependents. All insured participants are required to
45
46 participate in a biennial health checkup.² Approximately 94% of the insured participants
47
48 in 1992 and 1994 were examined biennially. We established a prospective cohort for
49
50 participants (aged 20-29) who routinely responded to the questionnaire on disease risk
51
52
53
54

1
2
3
4 factors and chronic diseases, naming this study the Korean Life Course Health Study
5 (KLCHS). The KLCHS cohort included 307,041 Koreans (142,461 males, 164,580
6 females) who were screened by KMIC in 1992 and 1994. Of these participants, 205,840
7 (67.0%) were registered in 1992 and 101,201 (33.0%) were registered in 1994.
8
9

10
11
12
13 Of these 307,041 participants, 71,760 (23.4%) who had incomplete data height, blood
14 pressure, fasting glucose, total cholesterol, or body mass index were excluded. We also
15 excluded 6,170 people from our analysis who reported a past history of cancer and
16 ASCVD, as well as 2,091 people who had missing information on smoking, exercise, or
17 alcohol drinking, and 65 people who died before start of follow-up. Female participants
18 were excluded, because of the low prevalence of smoking for females in Korea,
19 resulting in a total of 118,531 eligible participants for the analysis. The study proposal
20 obtained an approval by the Institutional Review Board of Human Research, Yonsei
21 University (4-2001-0029). This study was a retrospective cohort using past routine
22 laboratory data and did not receive consent.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 **Data collection**

39
40
41 The biennial KMIC screening was provided at local hospitals by medical practitioners
42 according to standard protocols. During the two-year interval examination from 1992 to
43 2008, we examined the variables related to the lifestyle of participants, such as daily
44 smoking amount, duration of smoking, and variables related to drinking. From data
45 collected at baseline, participants were defined as 'current smokers' if they were
46 smoking currently, 'never smokers' if they had no prior history of smoking, and 'ex-
47
48
49
50
51
52
53
54

1
2
3
4 smokers' if they had previously smoked but at the time of measurement did not smoke.
5
6 Current smokers were further categorized by amount of cigarettes consumed on average
7
8 per day (1–9, 10–19, and 20 or greater) as well as duration of smoking (1–9, 10–19, and
9
10 20 or more years) following the example of previous studies.^{2,10,11}
11

12
13 The definition of hypertension was a systolic BP \geq 140 mmHg or diastolic BP \geq 90
14
15 mmHg.¹² Body mass index (BMI) was measured as weight (kg) / height (m)². Serum
16
17 total cholesterol was grouped as desirable (<200 mg/dl), borderline-high (200-239
18
19 mg/dl), and high (\geq 240 mg/dl).¹³ Definition of diabetes was fasting blood glucose \geq
20
21 126 mg / dl.¹⁴
22
23
24
25
26
27
28

29 **Follow-up and outcomes**

30
31
32 The main outcome variables used in the analysis were morbidity and mortality
33
34 categorized by IHD, stroke, and ASCVD. For IHD, alone (ICD 10 codes, I20–I25),
35
36 acute myocardial infarction (AMI) alone (I21), and angina pectoris (AP) alone (ICD 10
37
38 codes, I20) are used. For stroke, stroke alone (I60-I69) was used. Finally, with regard to
39
40 ASCVD, we used total ASCVD, including disease of hypertensive (I10–I15), ischemic
41
42 heart disease (I20–I25), all stroke (I60–I69), other heart disease (I44–I51), sudden death
43
44 (R96), and other vascular disease (I70–I74).
45
46

47
48 The study outcomes were identified through diagnosis information recorded in hospital
49
50 admission, and from causes of death using death certificates. The study follow-up was
51
52 nearly 100% complete, as we were able to search ASCVD event data electronically by
53
54

1
2
3
4 KMIC registrants regarding the morbidity information of ASCVD. The period of
5
6 follow-up was 23 years from January 1st, 1993 to December 31st, 2015. Data on causes
7
8 of death were available during years 1993–2015, and incidence could be tracked during
9
10 years 1995–2015. The time frames over which these outcomes could be assessed varied
11
12 with data availability (Figure 1).
13

14
15 A validation study was conducted by 20 internists from the Korean Society of
16
17 Cardiology in 2009.¹⁵ For the participants who provided written permission for the use
18
19 of their personal information, 673 CHD events between 1994 and 2007 were confirmed
20
21 with individual hospital medical records, showing that 73% of designated myocardial
22
23 infarctions were valid. The validation study was updated in 2013 with a value of 93%.¹⁶
24
25
26 The validation study on mortality data has not been conducted.
27
28
29
30
31

32 **Statistical analysis**

33
34
35 First, we examined relationships between smoking status and established ASCVD risk
36
37 factors at baseline. In considering continuous ASCVD risk factors, we used ordinary
38
39 least squares regression and coded smoking quantity as an ordinal variable. In this study,
40
41 the Mantel Haenszel method was applied for dichotomous variables.¹⁷
42
43

44
45 To assess the independent effects of smoking on the risk of IHD, stroke, and ASCVD,
46
47 Cox proportional hazards models were used, controlling for age and the confounding
48
49 variables such as hypertension, diabetes, high cholesterol, and alcohol drinking. The
50
51 proportional assumption was also tested utilizing Schoenfeld residuals, and the survival
52
53 curve according to smoking status was plotted using the life-table method. We used
54

1
2
3
4 Levins formula for calculating population attributable risk (PAR).¹⁸ In additional
5
6 analyses, we excluded all events that had occurred in the first 4 years of follow-up.
7
8 These analyses ensured sensitivity in our results. In all analyses, a two-sided
9
10 significance level of 0.05 was used.
11
12
13
14
15

16 **Patient and Public Involvement**

17
18
19 Patients and or public were not involved.
20
21
22
23
24
25

26 **RESULTS**

27
28 The average age of the study participants was 26.7 ± 2.0 (SD) years. Among the
29
30 118,531 men, 78,455 (66.2%) were current smokers, 15,126 (12.8%) were ex-smokers,
31
32 and 92,403 (78%) had hypertension. For total cholesterol, 94,413 (79.7%) had a total
33
34 serum cholesterol level < 200 mg/dL, 19,764 (16.6%) had a borderline level of 200-240
35
36 mg/dL, and 4,444 (3.8%) had a level of 240 mg/dL or higher. In terms of amount of
37
38 smoking, 28.9% smoked more than 20 cigarettes per day while 45.5% and 25.6% of
39
40 current smokers smoked 1 to 9 and 10 to 19 cigarettes per day, respectively. Among
41
42 current smokers, 92.0% smoked for less than 10 years while 7.6% and 0.4% of current
43
44 smokers smoked for 10 to 19 years and more than 20 years, respectively.
45
46
47

48
49 Population characteristics by smoking status are presented in Table 1. After adjusting
50
51 for age, current smokers had a significantly higher body mass index (P for trend =
52
53 0.0056), higher consumption of alcohol drinking (P for trend $< .0001$), and higher
54

1
2
3
4 prevalence of diabetes (P for trend = 0.0060) than nonsmokers.
5

6
7 During 23 years of follow up (5,191,823 person-years), 2,786 (90 fatal) IHD cases
8
9 (53/100,000 person year), stroke cases 2,368 (126 fatal) (45.4/100,000 person year),
10
11 and 6,368 ASCVD cases (306 fatal) (122.7/100,000 person year) occurred
12

13
14 The independent effects of smoking on IHD, stroke, and ASCVD were analyzed
15
16 controlling for confounding factors through Cox proportional hazards models, as shown
17
18 in Table 2. The hazard ratios (HR) relating to IHD for current smokers were 1.5 (P
19
20 <.0001), and those of ex-smokers were 1.0 (P=0.8567). The HR of stroke was 1.4 (P
21
22 <.0001) for current smokers and 1.1 (P = 0.5008) on ex-smokers.
23

24
25 Compared to nonsmokers, the HR for any ASCVD event was 1.4 (P < 0.0001) in
26
27 current smokers and 1.1 in ex-smokers (P = 0.1406). Figure 2 shows the survival
28
29 probability by smoking history (never, former, 1-9, 10-19, ≥20 cigarette per day among
30
31 current smokers) and the corresponding unadjusted association with ASCVD. The
32
33 overall results demonstrated that smoking among young men increased the risk for
34
35 ASCVD relative to nonsmokers. After adjusting for age and traditional ASCVD risk
36
37 factors, the HRs for IHD and stroke were estimated for groups classified by amount of
38
39 smoking (A and B in Figure 3) and duration of smoking (C and D in Figure 3). For IHD
40
41 and stroke, the risk of events increased linearly with higher amount of cigarette per day
42
43 (P for trend, <.0001 and <.0001, respectively) and longer duration of smoking (P for
44
45 trend, <.0001 and <.0001, respectively) and longer duration of smoking (P for
46
47 trend, <.0001 and <.0001, respectively).
48
49

50
51 To examine whether serum total cholesterol levels could modify the effect of smoking
52
53 on ASCVD, we divided the cohort participants into quartile of total cholesterol. The
54

1
2
3
4 risks above were also found throughout the range of serum levels of cholesterol
5
6 demonstrating that serum total cholesterol levels did not modify the effect of smoking
7
8 on ASCVD (Figure 4).
9

10
11 Estimated risk factor prevalence in current studies of smoking and other additional risk
12
13 factors were used to estimate the PARs for IHD alone, stroke alone and total ASCVD
14
15 (Table 3). For IHD, current smoking accounts for about 24.9% of events, and
16
17 hypertension accounts for 8.1% of events. In the case of stroke, smoking was estimated
18
19 to account for 20.9%, whilst hypertension was estimated to be responsible for 13.3% of
20
21 stroke cases.
22
23
24
25
26

27 **DISCUSSION**

28
29 Our study investigated the association between smoking and risk of ASCVD among
30
31 Korean young men within a cohort study with a 23 year of follow-up. To our
32
33 knowledge, this is the first study focusing on Korean young adults. In our study,
34
35 smoking was the most crucial risk factor attributing to 20% of ASCVD mortality in
36
37 middle age.
38
39
40

41 Diabetes, hypertension, and hyperlipidemia are well known risk factors for ASCVD¹⁰.
42
43 However, for young adults with relatively low incidence of diabetes, hypertension and
44
45 hyperlipidemia, smoking is the most important and an independent risk factor for
46
47 predicting ASCVD in the present study. Furthermore, the high smoking rate among
48
49 young people is important with respect to the development of middle-aged hypertension
50
51 and transition to ASCVD.¹⁹⁻²⁰ Thus, middle-aged ASCVD morbidity is likely
52
53
54

1
2
3
4 predominantly predicted by smoking in young adulthood.
5

6
7 The body of research centered upon the health effects of smoking is steadily increasing,
8
9 with findings reported from many countries around the world. However, few studies
10
11 have examined the effect of smoking on ASCVD in young adults.²¹ Here, we present
12
13 evidence that current smoking is an independent risk factor affecting the incidence of
14
15 IHD, stroke and ASCVD.
16

17
18 These risk associations have been estimated across total serum cholesterol groups. A
19
20 cohort study in Hasayama Japan found that smoking showed positive association with
21
22 coronary heart disease in people with high levels of serum cholesterol above 180 mg /
23
24 dl, but not with people with low level of cholesterol less than 180 mg / dl.²²⁻²³
25
26 Afterward, six epidemiological studies were conducted. Among them, one study from
27
28 Puerto Rico Heart Health Program²⁴ showed similar results, but not all.⁷⁻¹¹ Of course,
29
30 all studies were conducted among adult populations. To the best of our knowledge, no
31
32 study has been done on young adults with much lower levels of serum cholesterol. In
33
34 addition, the high smoking rate among young adults is likely to be, even directly, linked
35
36 to high blood pressure among the adult population who developed ASCVD as a major
37
38 health problem.
39
40
41

42
43 In our analysis, there was no observed increase in risk of IHD or stroke among ex-
44
45 smokers. That is, the risk of ASCVD in ex-smokers was similar with that of never
46
47 smokers. These findings suggest that the risk of IHD lasts for an unknown period, while
48
49 the high risk for ASCVD decreases after smoking cessation. In this study, the risk of
50
51 ASCVD in ex-smokers was not significant. These findings can be interpreted in two
52
53

1
2
3
4 ways. First, it can be an effect on quitting smoking. Second, even if young people aged
5
6 20-29 quit smoking, they did not have a long period of life-time cigarette smoking,
7
8 which obviously did not have to do with the increased risk of heart disease. It is the part
9
10 that needs to be studied further. Previous studies shown that reducing adult smoking
11
12 pays more immediate dividends, both in terms of health improvements and cost
13
14 savings.²⁵ In particular, most of the excess risk of vascular mortality due to smoking in
15
16 women may be eliminated rapidly upon cessation and within 20 years for lung
17
18 diseases.²⁶ Although it is too late smoking cessation, cancer diagnosis itself may cause
19
20 smoking cessation.²⁷

21
22
23
24 There are several studies regarding cardiovascular risk among young people. According
25
26 to a study conducted by Bernaards et al.,²⁸ blood pressure and waist circumference were
27
28 decreased by lowering weekly tobacco consumption in younger participants. However,
29
30 they did not report the risk of developing cardiovascular disease events due to changes
31
32 in smoking. This seems to be another significant topic relating to the health of young
33
34 adults. Another study conducted by Morotti et al.²¹ on young women with polycystic
35
36 ovary syndrome (PCOS) reported an association between smoking habitude in lean
37
38 PCOS patients, and the increase of soft markers of cardiovascular risk. For young adult
39
40 African Americans, the association between cigarette smoking and carotid intima
41
42 assuming the genetic variation of smokers was reported and the -930^{A/G} polymorphism
43
44 modified the association among young healthy adults.²⁹ The study on association
45
46 between second hand smoking among childhood and cardiovascular event in adulthood
47
48 was conducted and found that the carotid plaque risk in adulthood is increased in
49
50 children whose parents had smoked.³⁰⁻³¹

1
2
3
4 This LCHS study has several strengths, such as high follow-up rates and a large,
5
6 national sample. The large sample size of cohort allowed us to investigate the
7
8 association of smoking with various levels of serum cholesterol. The civil servants and
9
10 private school teachers who participated in this study accounted for about 11% of the
11
12 total population in 1992. We did not compare the characteristics of the 89% population
13
14 not included in the study. Therefore, this study will not represent the whole population.
15
16 Moreover, selection bias may be a potential issue, since the final sample contains a
17
18 subset of over 118,531 young male adults (38.6%) out of 307,041 subjects initially
19
20 selected for our study. We therefore urge conservative interpretations of our study
21
22 results with regard to the general population.
23
24

25
26 In conclusion, smoking is a leading cause of ASCVD among young adults in Korea, a
27
28 country with a low total cholesterol level and a high smoking rate. Moreover, the
29
30 association was not modified by total cholesterol level. Smoking among Korean young
31
32 adult men was independently associated with increased risk of IHD, stroke and ASCVD.
33
34 The concentration of cholesterol in Korean men did not modify the effect of smoking
35
36 on ASCVD. Therefore, smoking cessation on young adult smokers is essential to
37
38 prevent CVD later in adult life. Moreover, clinical practice guidelines and policies
39
40 should emphasize to treat nicotine addiction in young smokers.
41
42
43
44
45
46

47 **Acknowledgments:** We appreciate the assistance of the Korean National Health
48
49 Insurance Service, which provided the data for this study.
50
51
52
53
54

1
2
3
4 **Contributors:** Data analysis was undertaken by YJ and KJJ. The article was drafted by
5
6 YJ. SL, JHB, SHJ, and SC substantially contributed to the conception or design of the
7
8 work, revising the work, approved the final version to be published, and agreed to be
9
10 accountable for all aspects of the work in ensuring that questions related to the accuracy
11
12 or integrity of any part of the work are appropriately investigated and resolved.
13
14

15
16
17
18 **Funding Sources:** This study was funded with a grant from the Korean Health
19
20 Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
21
22 (HI14C2686). The funder had no role in the study design and data collection, in
23
24 analyzing and interpreting data, or in the decision to submit this work for publication
25
26
27
28
29

30 **Conflict of interests:** None to declare.
31
32
33
34
35

36 **Ethics approval:** The study proposal obtained an approval by the Institutional Review
37
38 Board of Human Research, Yonsei University (4-2001-0029).
39
40

41 **Provenance and peer review:** Not commissioned; externally peer reviewed.
42
43
44

45 **Data sharing statement:** No additional data are available.
46
47
48
49
50
51
52
53

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Updated May 2017. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Visited at 3 March, 2018.
2. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. *Cancer Causes Control*. 2004;15(4):341-8.
3. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. *JAMA* 1996: 1646–50.
4. Liu B-Q, Peto R, Chen Z-M, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. *Br Med J* 1998;317: 1411–22.
5. Niu S-R, Yang G-H, Chen Z-M, et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. *Br Med J* 1998;317: 1423–24.
6. Robertson TL, Kato H, Gordon T, Kagan A, Rhoads GG, Land CE, Worth RM, Belsky JL, Dock DS, Miyanishi M, Kawamoto S. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. *Am J Cardiol*. 1977;39(2):244-9. PubMed PMID: 835483.
7. Lawlor DA, Song YM, Sung J, Ebrahim S, Smith GD. The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study. *Stroke*.

1
2
3
4 2008;39(3):760-7. doi: 10.1161/STROKEAHA.107.494823. Epub 2008 Jan 31.
5
6 PubMed PMID: 18239177.

7
8
9 8. Hozawa A, Okamura T, Kadowaki T, Murakami Y, Nakamura K, Hayakawa T, Kita Y,
10 Nakamura Y, Okayama A; Hirotsugu Ueshima for NIPPON DATA80 Research group.
11
12 Is weak association between cigarette smoking and cardiovascular disease mortality
13 observed in Japan explained by low total cholesterol? NIPPON DATA80. *Int J*
14
15
16
17 *Epidemiol.* 2007 Oct;36(5):1060-7. Epub 2007 Sep 10. PubMed PMID: 17846054.
18

19
20
21 9. Nakamura K, Barzi F, Huxley R, Lam TH, Suh I, Woo J, Kim HC, Feigin VL, Gu D,
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Woodward M; Asia Pacific Cohort Studies Collaboration. Does cigarette smoking
exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the
risk of cardiovascular diseases? *Heart.* 2009;95(11):909-16. doi:
10.1136/hrt.2008.147066. Epub 2009 Feb 5. PubMed PMID: 19196734.

10. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular
disease in men with low levels of serum cholesterol: the Korea Medical Insurance
Corporation Study. *JAMA.* 1999;282(22):2149-55.

11. Jee SH, Park J, Jo I, Lee J, Yun S, Yun JE, Jang Y. Smoking and atherosclerotic
cardiovascular disease in women with lower levels of serum cholesterol.
Atherosclerosis. 2007;190(2):306-12. Epub 2006 May 4.

12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones
DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and
Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure; National High Blood Pressure Education Program

1
2
3
4 Coordinating Committee. The Seventh Report of the Joint National Committee on
5
6 Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7
7
8 report. *JAMA*. 2003;289(19):2560-72. Epub 2003 May 14. Erratum in: *JAMA*. 2003 Jul
9
10 9;290(2):197. PubMed PMID: 12748199.

11
12
13 13. The National Cholesterol Education Program. Report of the Expert Panel on Blood
14
15 Cholesterol Levels in Children and Adolescents. NIH Publication No. 91-2732.
16
17 Bethesda, MD; 1994.

18
19
20 14. National Diabetes Data Group. Report of the Expert Committee on the Diagnostic
21
22 Classification of Diabetes. *Diabetes Care*. 1997;20(7):1183–97.

23
24
25 15. Kimm H, Yun JE, Lee SH, et al. Validity of the diagnosis of acute myocardial
26
27 infarction in Korean national medical health insurance claims data: the Korean Heart
28
29 Study (1). *Korean Circ J* 2012;42:10–15.

30
31
32 16. Kim HY. Validity of the diagnosis of acute myocardial infarction in Korean national
33
34 medical health insurance claims data: the Korean Heart Study [Master thesis]. Yonsei
35
36 University, Seoul, Korea, June 2013.

37
38
39 17. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1: The analysis of
40
41 case-control studies. Lyon, France: IARC Scientific Publication No. 32, pp. 146–50.

42
43
44 18. Levin ML. The occurrence of lung cancer in man. *Acta Intern Cancer* 1953;19:531.

45
46
47 19. Thut AB, Blizzard L, Schmidt MD, Luc PH, Granger RH, Dwyer T. The association
48
49 between smoking and hypertension in a population-based sample of Vietnamese men. *J*
50
51 *Hypertens*. 2010; 28: 245 – 50.

- 1
2
3
4 20. Kim BJ, Seo DC, Kim BS, Kang JH. Relationship between cotinine-verified
5 smoking status and incidence of hypertension in 74,743 Korean adults. *Circ J*. 2018 Feb
6 28. doi: 10.1253/circj.CJ-17-1188. [Epub ahead of print].
7
8
9
10
11 21. Morotti E, Battaglia B, Fabbri R, Paradisi R, Venturoli S, Battaglia C. Cigarette
12 smoking and cardiovascular risk in young women with polycystic ovary syndrome. *Int*
13 *J Fertil Steril*. 2014;7(4):301-12. Epub 2013 Dec 22.
14
15
16
17
18 22. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the
19 general population in Japan. *J Hypertens* 1990;8(Suppl 5):S9–S15.
20
21
22
23 23. Fujishima M, Kiyohara Y, Ueda K, Hasuo Y, Kato I, Iwamoto H. Smoking as
24 cardiovascular risk factor in low cholesterol population: the Hisayama Study. *Clin Exp*
25 *Hypertens A*. 1992;14(1-2):99-108.
26
27
28
29
30
31 24. Gordon T, Garcia-Palmier MR, Kagan A, Kannel WB, Schiffman J. Differences in
32 coronary heart disease in Framingham, Honolulu and Puerto Rico. *J Chronic Dis*.
33 1974;27:329–44.
34
35
36
37
38 25. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking
39 cessation: myocardial infarction and stroke. *Circulation*. 1997;96(4):1089-96.
40
41
42
43 26. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking
44 cessation in relation to mortality in women. *JAMA*. 2008;299(17):2037-47.
45
46
47
48 27. Westmaas JL, Newton CC, Stevens VL, Flanders WD, Gapstur SM, Jacobs EJ.
49 Does a Recent Cancer Diagnosis Predict Smoking Cessation? An Analysis From a
50 Large Prospective US Cohort. *J Clin Oncol*. 2015;33(15):1647-52.
51
52
53
54

1
2
3
4 28. Bornaards CM1, Twisk JW, Snel J, van Mechelen W, Kemper HC. In a prospective
5 study in young people, associations between changes in smoking behavior and risk
6 factors for cardiovascular disease were complex. *J Clin Epidemiol*. 2005
7 Nov;58(11):1165-71.

8
9
10
11
12
13 29. Murtaugh KH, Borde-Perry WC, Campbell KL, Gidding SS, Falkner B. Obesity,
14 smoking, and multiple cardiovascular risk factors in young adult African Americans.
15 *Ethn Dis*. 2002 Summer;12(3):331-5.

16
17
18
19
20 30. West HW, Juonala M, Gall SL, Kähönen M, Laitinen T, Taittonen L, Viikari JS,
21 aitakari OT, Magnussen CG. Exposure to parental smoking in childhood is associated
22 with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular
23 Risk in Young Finns Study. *Circulation*. 2015 Apr 7;131(14):1239-46. doi:
24 10.1161/CIRCULATIONAHA.114.013485. Epub 2015 Mar 23.

25
26
27
28
29
30
31
32 31. Roy MP, Steptoe A, Kirschbaum C. Association between smoking status and
33 cardiovascular and cortisol stress responsivity in healthy young men. *Int J Behav Med*.
34 1994;1(3):264-83.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Figure legends

Figure 1. Timeline for data collection in the Korean Life Course Health Study

Figure 2. Survival of atherosclerotic cardiovascular disease event by smoking history in Korean young adult men, 1992-2015

Figure 3. Hazard ratios with 95% confidence intervals for from ischemic heart disease, and stroke by cigarette per day and duration of smoking

Figure 4. Hazard ratios with 95% confidence intervals for ischemic heart disease and stroke by total cholesterol groups of smokers compared with nonsmokers: Each group of total cholesterol levels are as follows: first, 149 mg/dl; second, 150-169 mg/dL; third, 170-194 mg/dL; fourth, ≥ 195 mg/dL. The reference group is non-smokers in each quartile of total cholesterol.

Table 1. Baseline Characteristics of the Korean Life Course Health Study, 1992-1994, According to Smoking Status*

Characteristic	Nonsmokers (n=24,950)	Ex-smokers (n=15,126)	No. of cigarettes per day among current smokers			P for Trend [¶]
			1-9 (n=22,642)	10-19 (n=35,690)	≥20 (n=20,123)	
Age, year	26.6 (2.1)	26.9 (1.9)	26.6 (2.0)	26.8 (1.9)	26.8 (1.9)	0.1622
Systolic Blood Pressure, mmHg	120.4 (11.6)	120.0 (11.8)	119.8 (11.6)	120.1 (11.6)	120.3 (11.6)	0.2558
Diastolic Blood Pressure mmHg	78.0 (9.0)	77.7 (9.1)	77.5 (9.0)	77.8 (9.0)	78.0 (9.0)	0.1122
Total cholesterol, mg/dL	173.4 (32.9)	173.4 (32.6)	172.9 (33.1)	174.5 (33.4)	177.2 (34.4)	0.9543
Body mass index, kg/m ²	22.3 (2.4)	22.4 (2.4)	22.3 (2.4)	22.5 (2.5)	22.9 (2.6)	0.0056
Fasting serum glucose, mg/dL	86.7 (13.3)	86.6 (13.5)	86.2 (14.1)	86.4 (14.1)	86.6 (15.3)	0.4821
Alcohol consumption, g per day	7.3 (17.7)	9.7 (19.7)	12.2 (22.6)	14.5 (25.1)	20.4 (36.1)	<.0001
Conditions, %						
Hypertension [†]	15.7	15.1	14.5	15.6	15.7	0.7987
Hypercholesterolemia [‡]	3.4	3.3	3.3	3.9	4.7	0.0743
Diabetes [§]	0.7	0.8	0.9	0.9	1.0	0.0060
Alcohol use	61.2	81.3	88.2	88.3	86.9	0.1035
Physical activity	24.9	26.8	22.9	17.5	13.0	<.0001

*Data are expressed as means (SD) unless otherwise indicated; †Systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least

1
2
3
4
5 90 mmHg; ‡Total cholesterol level of at least 6.21 mmol/L (240 mg/dL); § Fasting serum glucose value of at least 6.99 mmol/L (126 mg/L); || Consumption
6
7 of Soju which is a colorless distilled beverage of Korean origin; ¶Testing for trend across nonsmokers and current smokers; ex-smokers were excluded.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2. Risk of Morbidity from Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men in the Korean Life Course Health Study, 1992-2015*

Variables and Categories	Ischemic Heart Disease		Cerebrovascular Disease		Atherosclerotic Cardiovascular Disease	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age (5-year age group)	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.3 (1.2 – 1.4)	<.0001
Cigarette smoking						
Ex-smoker	1.0 (0.9 – 1.2)	0.8567	1.1 (0.9 – 1.3)	0.5008	1.1 (1.0 – 1.2)	0.1406
Current smoker	1.5 (1.3 – 1.6)	<.0001	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
Blood Pressure†						
High normal	1.2 (1.1 – 1.4)	<.0001	1.2 (1.0 – 1.3)	0.0152	1.2 (1.1 – 1.3)	<.0001
Stage 1 hypertension	1.6 (1.4 – 1.8)	<.0001	1.7 (1.5 – 2.0)	<.0001	1.7 (1.5 – 1.8)	<.0001
Stage 2 hypertension	2.0 (1.6 – 2.5)	<.0001	3.2 (2.5 – 4.0)	<.0001	2.9 (2.5 – 3.3)	<.0001
Total cholesterol‡						
Borderline-high cholesterol	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
High cholesterol	2.5 (2.1 – 2.8)	<.0001	1.7 (1.4 – 2.1)	<.0001	2.1 (1.8 – 2.3)	<.0001
Fasting blood sugar§						
Diabetes	1.3 (0.9 – 1.9)	0.1375	1.6 (1.1 – 2.3)	0.0222	1.5 (1.2 – 1.9)	0.0008
Physical activity						
No exercise	1.1 (1.0 – 1.3)	0.0122	1.1 (1.0 – 1.3)	0.2156	1.1 (1.0 – 1.3)	0.0075

*Hazard ratio (HRs) and 95% confidence intervals (CIs) from multivariable Cox proportional hazards models. †The reference category is normal (systolic

1
2
3
4
5 blood pressure<140 mmHg and diastolic blood pressure<90mm Hg). ‡ The reference category is desirable (serum cholesterol level, < 5.17 mmol/L [200
6 mg/dL]). §The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47


For peer review only

Table 3. Population Attributable Risks (PARs) and 95% Confidence Intervals (CIs) From Smoking and Other Risk Factors of Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men: The Korean Life Course Health Study

Variables and Categories	Prevalence %	Ischemic Heart Disease PAR (95% CI)	Cerebrovascular Disease PAR (95% CI)	Atherosclerotic Cardiovascular Disease PAR (95% CI)
Smoking				
Current smoker	66.2	24.9 (16.6 – 28.4)	20.9 (11.7 – 28.4)	20.9 (16.5 – 24.9)
Blood Pressure*				
Hypertension	22.0	8.1 (6.2 – 9.9)	13.3 (9.9 – 14.9)	9.9 (9.9 – 11.7)
Total cholesterol†				
Borderline	16.6	6.2 (4.7 – 9.1)	6.2 (4.7 – 7.7)	6.2 (4.7 – 7.6)
High	3.8	5.4 (4.0 – 6.4)	4.0 (2.9 – 4.7)	4.0 (2.9 – 4.7)
Fasting blood sugar‡				
Diabetes	0.9	0.3 (-0.9 – 0.8)	0.5 (0.08 – 1.1)	0.4 (0.2 – 0.8)
Physical activity				
No exercise	0.8	7.4 (0 – 19.3)	7.4 (0 – 19.3)	7.4 (0 – 19.3)

*The reference category is normal (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90mm Hg). †The reference category is desirable (serum cholesterol level < 5.17 mmol/L [200 mg/dL]). ‡ The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).

Figure 1



69x33mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2


254x190mm (300 x 300 DPI)

Figure 3.


A. Ischemic Heart Disease




B. Ischemic Heart Disease




C. Stroke




D. Stroke



E. ASCVD




F. ASCVD



46x53mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.



46x94mm (300 x 300 DPI)

Title: *smoking is the first leading cause of cardiovascular disease in Young Men.*

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	①	(a) Indicate the study's design with a commonly used term in the title or the abstract <i>Page 3</i> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <i>page 3</i>
Introduction		
Background/rationale	②	Explain the scientific background and rationale for the investigation being reported <i>page 5</i>
Objectives	③	State specific objectives, including any prespecified hypotheses <i>page 6, para 1.</i>
Methods		
Study design	④	Present key elements of study design early in the paper <i>Page 6, para 2</i>
Setting	⑤	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <i>page 6-7.</i>
Participants	⑥	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>page 6, page 8</i> (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	⑦	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <i>page 7, para 3, page 8</i>
Data sources/ measurement	⑧*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <i>page 6, page 7</i>
Bias	⑨	Describe any efforts to address potential sources of bias <i>page 14.</i>
Study size	⑩	Explain how the study size was arrived at <i>page 7</i>
Quantitative variables	⑪	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>page 8</i>
Statistical methods	⑫	(a) Describe all statistical methods, including those used to control for confounding <i>page 9</i> (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed <i>page 8</i> (e) Describe any sensitivity analyses <i>page 9-10</i>
Results		
Participants	⑬*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <i>page 10</i> (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram <i>page 7. (Figure 1)</i>
Descriptive data	⑭*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <i>page 10</i> (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) <i>page 10 (23 years of follow-up)</i>
Outcome data	⑮*	Report numbers of outcome events or summary measures over time <i>page 10.</i>
Main results	⑯	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <i>page 10, para 1 (Table 2)</i> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	page 11 (Figure 4)
2	Discussion			
3	Key results	18	Summarise key results with reference to study objectives	page 12 para 2
4	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 14, para 2.
5	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 14
6	Generalisability	21	Discuss the generalisability (external validity) of the study results	page 14
7	Other information			
8	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean Life Course Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024453.R2
Article Type:	Research
Date Submitted by the Author:	24-Nov-2018
Complete List of Authors:	Jee, Yongho; Seoul National University, Department of Public Health Jung, Keum Ji; Yonsei University Graduate School Institute for Health Promotion, Dept. of Public Health Lee, Sunmi; National Health Insurance Service, Health Insurance Policy Research Institute Back, Joung Hwan; Health Insurance Policy Research Institute Jee, Sun Ha; Graduate School of Public Health, Yonsei University, Epidemiology Cho, Sung-il ; Seoul National University, Department of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Smoking and tobacco, Public health, Cardiovascular medicine
Keywords:	Smoking, Cardiovascular Disease, Young adults

SCHOLARONE™
Manuscripts

1
2
3
4 Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean
5
6 Life Course Health Study
7
8
9

10
11 Yongho Jee, MPH^{1,2}, Keum Ji Jung, PhD^{2,4}, Sunmi Lee, PhD³, Joung Hwan Back, PhD³,
12
13 Sun Ha Jee, PhD^{2,4*}, Sung-il Cho, MD, PhD^{1*}
14
15

16
17
18 ¹ Department of Public Health, Seoul National University, Seoul, Republic of Korea
19

20
21 ² Institute for Health Promotion, Graduate School of Public Health, Yonsei University,
22
23 Seoul, Republic of Korea
24

25
26 ³ Health Insurance Policy Research Institute, Wonju, Republic of Korea
27

28
29 ⁴ Department of Epidemiology and Health Promotion, Graduate School of Public
30
31 Health, Yonsei University, Seoul, Republic of Korea
32
33

34
35
36
37
38 Running title: Smoking is the first leading cause of Cardiovascular Disease
39

40
41
42
43 *These last authors contributed equally to this work
44

45
46
47 *Corresponding authors. Department of Epidemiology and Health Promotion, Graduate
48
49 School of Public Health, Yonsei University, Seoul, Republic of Korea.
50

51
52 E-mail address: jsunha@yuhs.ac (S.H. Jee).

53
54 Department of Public Health, Seoul National University, Seoul, Republic of Korea
55

56
57 E-mail address: scho@snu.ac.kr (S.I. Cho).
58

1
2
3
4 These two authors equally contributed as corresponding author.
5
6
7

8
9 Word count: 3828
10

11 Table 3, Figure 4
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: To examine the effect of smoking on risk of atherosclerotic cardiovascular disease (ASCVD) in Korean young men and to examine whether serum total cholesterol levels could modify the effect of smoking on ASCVD.

Design: A prospective cohort study within a national insurance system.

Setting: Health screenings provided by national insurance in 1992 and 1994.

Participants: 118,531 young men between 20 and 29 years of age and were followed up for 23 years.

Outcome measure: To assess the independent effects of smoking on the risk of Ischemic Heart Disease (IHD), stroke, and ASCVD, Cox proportional hazards regression models were used, controlling for age, hypertension, diabetes, hypercholesterolemia, and alcohol drinking.

Results: The total number of current smokers was 78,455 (66.2%), and 94,113 (79.7%) of the sample recorded a total cholesterol level < 200 mg/dl measured at baseline. Between 1993 and 2015, 2,786 cases of IHD (53/100,000 person year), 2,368 cases of stroke (45.4/100,000 person year), and 6,368 ASCVD (122.7/100,000 person year) occurred. The risk of IHD, stroke, and total ASCVD events was found to increase for current smokers, with a hazard ratios (HR) with 95% Confidence Interval (CI) of 1.5 (95% CI: 1.3,1.6), 1.4 (95% CI: 1.2,1.6), and 1.4 (95% CI: 1.3,1.5), respectively. Further, the risks above were also found throughout the range of serum levels of cholesterol.

1
2
3
4 **Conclusions:** Smoking among Korean young adult men was independently associated
5
6 with increased risk of IHD, stroke and ASCVD. The concentration of cholesterol in
7
8 Korean men did not modify the effect of smoking on ASCVD.
9
10

11 **Keywords:** Smoking, Cardiovascular Disease, Young adults
12
13
14
15
16
17
18
19
20
21
22
23

24 **Strengths and limitations of this study**

- 25
26
27 ▪ Novel result from Korean young adults is that smoking is the first leading cause of
28
29 Cardiovascular Disease (CVD) while smoking is the second leading cause of CVD in
30
31 middle aged adults.
32
- 33
34
35 ▪ The large sample size of cohort with 118,531 young men between 20 and 29 years of
36
37 age and were followed up for 23 years.
38
- 39
40
41 ▪ The limitations of this study include possible measurement errors and the non-random
42
43 sample used.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death globally, with more people dying from ASCVD than any other causes of death annually. A total of 17.7 million people died as a result of ASCVDs in 2015 globally, comprising 31% of all deaths. Of these deaths, 7.4 million are estimated to have been the result of coronary heart disease, whilst 6.7 million were due to stroke¹. According to previous studies published in the western countries, tobacco use has been reported to be a major risk factor for ASCVD following hypertension.¹

A growing concern is that for young adults, cigarette smoking may be the first leading cause of ASCVD, owing to the high prevalence of cigarette smoking in comparison to lower levels of alternate risk factors, including hypertension, diabetes, and high cholesterol levels. However, despite these observations, there remain only a small number of studies considering the relationship between smoking and ASCVD in Korea and other countries in East Asia.²⁻⁵

Further, comparisons with Western populations may be less informative owing to the relatively lower levels of cholesterol commonly present in Asian countries. Biological studies have explored the interaction between smoking and serum cholesterol levels.⁶⁻⁹ Nevertheless, very few studies have analyzed the interaction effects of smoking and serum cholesterol on ASCVD in young adults

‘World No Tobacco Day 2018’ is a campaign, with the primary objective of raising awareness of the link between tobacco use and negative health outcomes, predominantly heart and other cardiovascular diseases (CVD) including stroke. It will

1
2
3
4 also seek to expand the range of potential strategies key public actors such as
5
6 governmental and public bodies can take to reduce the health risks of tobacco use. If
7
8 there is an established link between tobacco smoking in young adults and CVD, the
9
10 campaign will further increase awareness on smoking in young adults. The government
11
12 and the public can then subsequently take actions to reduce risks of smoking at earlier
13
14 stage. Unfortunately, however, the association between smoking and CVD in young
15
16 adults has not received much attention because at least a long term (over 20 years)
17
18 follow-up study is needed. This serves as motivation for this study, in which we aimed
19
20 to examine the effect of smoking on risk of ASCVD in Korean young adults with
21
22 relatively low serum cholesterol levels. We also investigated whether the effect of
23
24 smoking can be modified by serum levels of cholesterol.
25
26
27
28
29
30
31
32

33 **METHOD**

34 **Study participants**

35
36
37
38 In Korea, the Korean Medical Insurance Corporation (KMIC) provided health insurance
39
40 for private school staff and civil servants prior to the current insurance system, under
41
42 which it was integrated as National Health Insurance.² A total of 4,862,438 (10.7%) of
43
44 the Korean population were covered by KMIC insurance, of which 1,297,833 were
45
46 employees, and 3,364,605 were dependents. All insured participants are required to
47
48 participate in a biennial health checkup.² Approximately 94% of the insured participants
49
50 in 1992 and 1994 were examined biennially. We established a prospective cohort for
51
52 participants (aged 20-29) who routinely responded to the questionnaire on disease risk
53
54
55
56
57
58
59
60

1
2
3
4 factors and chronic diseases, naming this study the Korean Life Course Health Study
5 (KLCHS). The KLCHS cohort included 307,041 Koreans (142,461 males, 164,580
6
7 females) who were screened by KMIC in 1992 and 1994. Of these participants, 205,840
8
9 (67.0%) were registered in 1992 and 101,201 (33.0%) were registered in 1994.
10
11
12

13
14 Of these 307,041 participants, 71,760 (23.4%) who had incomplete data height, blood
15
16 pressure, fasting glucose, total cholesterol, or body mass index were excluded. We also
17
18 excluded 6,170 people from our analysis who reported a past history of cancer and
19
20 ASCVD, as well as 2,091 people who had missing information on smoking, exercise, or
21
22 alcohol drinking, and 65 people who died before start of follow-up. Female participants
23
24 were excluded, because of the low prevalence of smoking for females in Korea,
25
26 resulting in a total of 118,531 eligible participants for the analysis. The study proposal
27
28 obtained an approval by the Institutional Review Board of Human Research, Yonsei
29
30 University (4-2001-0029). This study was a retrospective cohort using past routine
31
32 laboratory data and did not receive consent.
33
34
35
36
37
38
39
40

41 **Data collection**

42
43
44 The biennial KMIC screening was provided at local hospitals by medical practitioners
45
46 according to standard protocols. During the two-year interval examination from 1992 to
47
48 2008, we examined the variables related to the lifestyle of participants, such as daily
49
50 smoking amount, duration of smoking, and variables related to drinking. From data
51
52 collected at baseline, participants were defined as ‘current smokers’ if they were
53
54 smoking currently, ‘never smokers’ if they had no prior history of smoking, and ‘ex-
55
56
57
58
59
60

1
2
3
4 smokers' if they had previously smoked but at the time of measurement did not smoke.
5
6 Current smokers were further categorized by amount of cigarettes consumed on average
7
8 per day (1–9, 10–19, and 20 or greater) as well as duration of smoking (1–9, 10–19, and
9
10 20 or more years) following the example of previous studies.^{2,10,11}
11
12

13
14 The definition of hypertension was a systolic BP \geq 140 mmHg or diastolic BP \geq 90
15
16 mmHg.¹² Body mass index (BMI) was measured as weight (kg) / height (m)². Serum
17
18 total cholesterol was grouped as desirable ($<$ 200 mg/dl), borderline-high (200-239
19
20 mg/dl), and high (\geq 240 mg/dl).¹³ Definition of diabetes was fasting blood glucose \geq
21
22 126 mg / dl.¹⁴
23
24
25
26
27
28
29
30

31 **Follow-up and outcomes**

32
33 The main outcome variables used in the analysis were morbidity and mortality
34
35 categorized by IHD, stroke, and ASCVD. For IHD, alone (ICD 10 codes, I20–I25),
36
37 acute myocardial infarction (AMI) alone (I21), and angina pectoris (AP) alone (ICD 10
38
39 codes, I20) are used. For stroke, stroke alone (I60–I69) was used. Finally, with regard to
40
41 ASCVD, we used total ASCVD, including disease of hypertensive (I10–I15), ischemic
42
43 heart disease (I20–I25), all stroke (I60–I69), other heart disease (I44–I51), sudden death
44
45 (R96), and other vascular disease (I70–I74).
46
47
48
49
50

51 The study outcomes were identified through diagnosis information recorded in hospital
52
53 admission, and from causes of death using death certificates. The study follow-up was
54
55 nearly 100% complete, as we were able to search ASCVD event data electronically by
56
57
58
59
60

1
2
3
4 KMIC registrants regarding the morbidity information of ASCVD. The period of
5
6 follow-up was 23 years from January 1st, 1993 to December 31st, 2015. Data on causes
7
8 of death were available during years 1993–2015, and incidence could be tracked during
9
10 years 1995–2015. The time frames over which these outcomes could be assessed varied
11
12 with data availability (Figure 1).
13
14

15
16 A validation study was conducted by 20 internists from the Korean Society of
17
18 Cardiology in 2009.¹⁵ For the participants who provided written permission for the use
19
20 of their personal information, 673 CHD events between 1994 and 2007 were confirmed
21
22 with individual hospital medical records, showing that 73% of designated myocardial
23
24 infarctions were valid. The validation study was updated in 2013 with a value of 93%.¹⁶
25
26 The validation study on mortality data has not been conducted.
27
28
29
30
31
32
33

34 **Statistical analysis**

35
36
37 First, we examined relationships between smoking status and established ASCVD risk
38
39 factors at baseline. In considering continuous ASCVD risk factors, we used ordinary
40
41 least squares regression and coded smoking quantity as an ordinal variable. In this
42
43 study, the Mantel Haenszel method was applied for dichotomous variables.¹⁷
44
45
46

47
48 To assess the independent effects of smoking on the risk of IHD, stroke, and ASCVD,
49
50 Cox proportional hazards models were used, controlling for age and the confounding
51
52 variables such as hypertension, diabetes, high cholesterol, and alcohol drinking. The
53
54 proportional assumption was also tested utilizing Schoenfeld residuals, and the survival
55
56 curve according to smoking status was plotted using the life-table method. We used
57
58
59
60

1
2
3
4 Levins formula for calculating population attributable risk (PAR).¹⁸ In additional
5
6 analyses, we excluded all events that had occurred in the first 4 years of follow-up.
7
8 These analyses ensured sensitivity in our results. In all analyses, a two-sided
9
10 significance level of 0.05 was used.
11
12
13
14
15
16

17 **Patient and Public Involvement**

18
19
20 Patients and or public were not involved.
21
22
23
24
25

26 **RESULTS**

27
28 The average age of the study participants was 26.7 ± 2.0 (SD) years. Among the
29
30 118,531 men, 78,455 (66.2%) were current smokers, 15,126 (12.8%) were ex-smokers,
31
32 and 92,403 (15.4%) had hypertension. For total cholesterol, 94,413 (79.7%) had a total
33
34 serum cholesterol level < 200 mg/dL, 19,764 (16.6%) had a borderline level of 200-240
35
36 mg/dL, and 4,444 (3.8%) had a level of 240 mg/dL or higher. In terms of amount of
37
38 smoking, 28.9% smoked more than 20 cigarettes per day while 45.5% and 25.6% of
39
40 current smokers smoked 1 to 9 and 10 to 19 cigarettes per day, respectively. Among
41
42 current smokers, 92.0% smoked for less than 10 years while 7.6% and 0.4% of current
43
44 smokers smoked for 10 to 19 years and more than 20 years, respectively.
45
46
47
48

49
50 Population characteristics by smoking status are presented in Table 1. After adjusting
51
52 for age, current smokers had a significantly higher body mass index (P for trend =
53
54 0.0056), higher consumption of alcohol drinking (P for trend $< .0001$), and higher
55
56 prevalence of diabetes (P for trend = 0.0060) than nonsmokers.
57
58

1
2
3
4 During 23 years of follow up (5,191,823 person-years), 2,786 (90 fatal) IHD cases
5
6 (53/100,000 person year), stroke cases 2,368 (126 fatal) (45.4/100,000 person year),
7
8 and 6,368 ASCVD cases (306 fatal) (122.7/100,000 person year) occurred
9

10
11
12 The independent effects of smoking on IHD, stroke, and ASCVD were analyzed
13
14 controlling for confounding factors through Cox proportional hazards models, as shown
15
16 in Table 2. The hazard ratios (HR) relating to IHD for current smokers were 1.5 (P
17
18 <.0001), and those of ex-smokers were 1.0 (P=0.8567). The HR of stroke was 1.4 (P
19
20 <.0001) for current smokers and 1.1 (P = 0.5008) on ex-smokers.
21
22

23
24 Compared to nonsmokers, the HR for any ASCVD event was 1.4 (P < 0.0001) in
25
26 current smokers and 1.1 in ex-smokers (P = 0.1406). Figure 2 shows the survival
27
28 probability by smoking history (never, former, 1-9, 10-19, \geq 20 cigarette per day
29
30 among current smokers) and the corresponding unadjusted association with ASCVD.
31
32 The overall results demonstrated that smoking among young men increased the risk for
33
34 ASCVD relative to nonsmokers. After adjusting for age and traditional ASCVD risk
35
36 factors, the HRs for IHD and stroke were estimated for groups classified by amount of
37
38 smoking (A and B in Figure 3) and duration of smoking (C and D in Figure 3). For IHD
39
40 and stroke, the risk of events increased linearly with higher amount of cigarette per day
41
42 (P for trend, <.0001 and <.0001, respectively) and longer duration of smoking (P for
43
44 trend, <.0001 and <.0001, respectively).
45
46
47
48
49

50
51 To examine whether serum total cholesterol levels could modify the effect of smoking
52
53 on ASCVD, we divided the cohort participants into quartile of total cholesterol. The
54
55 risks above were also found throughout the range of serum levels of cholesterol
56
57

1
2
3
4 demonstrating that serum total cholesterol levels did not modify the effect of smoking
5
6 on ASCVD (Figure 4).
7
8

9
10 Estimated risk factor prevalence in current studies of smoking and other additional risk
11
12 factors were used to estimate the PARs for IHD alone, stroke alone and total ASCVD
13
14 (Table 3). For IHD, current smoking accounts for about 24.9% of events, and
15
16 hypertension accounts for 8.1% of events. In the case of stroke, smoking was estimated
17
18 to account for 20.9%, whilst hypertension was estimated to be responsible for 13.3% of
19
20 stroke cases.
21
22

23 24 25 26 27 **DISCUSSION**

28
29 Our study investigated the association between smoking and risk of ASCVD among
30
31 Korean young men within a cohort study with a 23 year of follow-up. To our
32
33 knowledge, this is the first study focusing on Korean young adults. In our study,
34
35 smoking was the most crucial risk factor attributing to 20% of ASCVD mortality in
36
37 middle age.
38
39

40
41
42 Diabetes, hypertension, and hyperlipidemia are well known risk factors for ASCVD¹⁰.
43
44 However, for young adults with relatively low incidence of diabetes, hypertension and
45
46 hyperlipidemia, smoking is the most important and an independent risk factor for
47
48 predicting ASCVD in the present study. Furthermore, the high smoking rate among
49
50 young people is important with respect to the development of middle-aged hypertension
51
52 and transition to ASCVD.¹⁹⁻²⁰ Thus, middle-aged ASCVD morbidity is likely
53
54 predominantly predicted by smoking in young adulthood.
55
56
57

1
2
3
4 The body of research centered upon the health effects of smoking is steadily increasing,
5
6 with findings reported from many countries around the world. However, few studies
7
8 have examined the effect of smoking on ASCVD in young adults.²¹ Here, we present
9
10 evidence that current smoking is an independent risk factor affecting the incidence of
11
12 IHD, stroke and ASCVD.
13
14

15
16 These risk associations have been estimated across total serum cholesterol groups. A
17
18 cohort study in Hasayama Japan found that smoking showed positive association with
19
20 coronary heart disease in people with high levels of serum cholesterol above 180 mg /
21
22 dl, but not with people with low level of cholesterol less than 180 mg / dl.²²⁻²³
23
24 Afterward, six epidemiological studies were conducted. Among them, one study from
25
26 Puerto Rico Heart Health Program²⁴ showed similar results, but not all.⁷⁻¹¹ Of course,
27
28 all studies were conducted among adult populations. To the best of our knowledge, no
29
30 study has been done on young adults with much lower levels of serum cholesterol. In
31
32 addition, the high smoking rate among young adults is likely to be, even directly, linked
33
34 to high blood pressure among the adult population who developed ASCVD as a major
35
36 health problem.
37
38
39
40
41

42
43 In this study, the non-significant risk of ASCVD among ex-smokers can be interpreted
44
45 in two ways. First, this result may simply reflect the effect of smoking cessation. Most
46
47 previous studies have shown that the effects of smoking cessation are immediate in
48
49 CVD (most of the excess risk of vascular mortality due to smoking may be eliminated
50
51 rapidly upon cessation), while lung cancer occurs within 20 years^{25, 26}. In particular,
52
53 most of the excess risk of vascular mortality due to smoking in women may be
54
55 eliminated rapidly upon cessation and within 20 years for lung diseases.²⁶ Second,
56
57 even if a number of young adult ex-smokers, aged 20-29 years, may have smoked
58
59 continuously from adolescence, it is still a short term of smoking, compared to adults.
60
Previous study shown that reducing adult smoking pays more immediate dividends,
both in terms of health improvements and cost savings.²⁷ While present study lacks

1
2
3
4 information on smoking duration of ex-smokers, current smokers who continued to
5 smoke seem to have increased risk of CVD by 40%. Therefore, while the smoking
6 duration of ex-smokers is unknown, it may be reasonable to consider the results were
7 mainly affected by the smoking cessation. Further research on the effects of smoking
8 cessation among young adults is necessary.
9
10

11 There are several studies regarding cardiovascular risk among young people. According
12 to a study conducted by Bernaards et al.,²⁸ blood pressure and waist circumference were
13 decreased by lowering weekly tobacco consumption in younger participants. However,
14 they did not report the risk of developing cardiovascular disease events due to changes
15 in smoking. This seems to be another significant topic relating to the health of young
16 adults. Another study conducted by Morotti et al.²¹ on young women with polycystic
17 ovary syndrome (PCOS) reported an association between smoking habitude in lean
18 PCOS patients, and the increase of soft markers of cardiovascular risk. For young adult
19 African Americans, the association between cigarette smoking and carotid intima
20 assuming the genetic variation of smokers was reported and the -930^{A/G} polymorphism
21 modified the association among young healthy adults.²⁹ The study on association
22 between second hand smoking among childhood and cardiovascular event in adulthood
23 was conducted and found that the carotid plaque risk in adulthood is increased in
24 children whose parents had smoked.³⁰⁻³¹
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 This LCHS study has several strengths, such as high follow-up rates and a large,
46 national sample. The large sample size of cohort allowed us to investigate the
47 association of smoking with various levels of serum cholesterol. The civil servants and
48 private school teachers who participated in this study accounted for about 11% of the
49 total population in 1992. We did not compare the characteristics of the 89% population
50 not included in the study. Therefore, this study will not represent the whole population.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Moreover, selection bias may be a potential issue, since the final sample contains a
5 subset of over 118,531 young male adults (38.6%) out of 307,041 subjects initially
6 selected for our study. We therefore urge conservative interpretations of our study
7 results with regard to the general population.
8
9
10
11
12
13

14 In conclusion, smoking is a leading cause of ASCVD among young adults in Korea, a
15 country with a low total cholesterol level and a high smoking rate. Moreover, the
16 association was not modified by total cholesterol level. Smoking among Korean young
17 adult men was independently associated with increased risk of IHD, stroke and
18 ASCVD. The concentration of cholesterol in Korean men did not modify the effect of
19 smoking on ASCVD. Therefore, smoking cessation on young adult smokers is essential
20 to prevent CVD later in adult life. Moreover, clinical practice guidelines and policies
21 should emphasize to treat nicotine addiction in young smokers.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Acknowledgments:** We appreciate the assistance of the Korean National Health
41 Insurance Service, which provided the data for this study.
42
43
44
45
46
47

48 **Contributors:** Data analysis was undertaken by YJ and KJJ. The article was drafted by
49 YJ. SL, JHB, SHJ, and SC substantially contributed to the conception or design of the
50 work, revising the work, approved the final version to be published, and agreed to be
51 accountable for all aspects of the work in ensuring that questions related to the accuracy
52
53
54
55
56
57
58
59
60

1
2
3
4 or integrity of any part of the work are appropriately investigated and resolved.
5
6
7
8
9

10 **Funding Sources:** This study was funded with a grant from the Korean Health
11 Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
12 (HI14C2686). The funder had no role in the study design and data collection, in
13 analyzing and interpreting data, or in the decision to submit this work for publication
14
15
16
17
18
19

20
21
22
23 **Conflict of interests:** None declared
24
25
26
27
28

29 **Ethics approval:** The study proposal obtained an approval by the Institutional Review
30 Board of Human Research, Yonsei University (4-2001-0029).
31
32
33

34 **Provenance and peer review:** Not commissioned; externally peer reviewed.
35
36
37
38

39 **Data sharing statement:** No additional data are available.
40

41 REFERENCES

- 42
43 1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Updated
44 May 2017. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Visited at 3 March,
45 2018.
46
47
48
49
50
51 2. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean
52 men and women. *Cancer Causes Control*. 2004;15(4):341-8.
53
54
55
56
57 3. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and
58
59
60

1
2
3
4 mortality in relation to cigarette smoking in Shanghai, China. *JAMA* 1996: 1646–50.

5
6
7 4. Liu B-Q, Peto R, Chen Z-M, et al. Emerging tobacco hazards in China: 1.
8 Retrospective proportional mortality study of one million deaths. *Br Med J* 1998;317:
9 1411–22.

10
11
12
13
14
15 5. Niu S-R, Yang G-H, Chen Z-M, et al. Emerging tobacco hazards in China: 2. Early
16 mortality results from a prospective study. *Br Med J* 1998;317: 1423–24.

17
18
19
20
21 6. Robertson TL, Kato H, Gordon T, Kagan A, Rhoads GG, Land CE, Worth RM,
22 Belsky JL, Dock DS, Miyanishi M, Kawamoto S. Epidemiologic studies of coronary
23 heart disease and stroke in Japanese men living in Japan, Hawaii and California.
24 Coronary heart disease risk factors in Japan and Hawaii. *Am J Cardiol.* 1977;39(2):244-

25
26
27
28
29 9. PubMed PMID: 835483.

30
31
32
33 7. Lawlor DA, Song YM, Sung J, Ebrahim S, Smith GD. The association of smoking
34 and cardiovascular disease in a population with low cholesterol levels: a study of
35 648,346 men from the Korean national health system prospective cohort study. *Stroke.*
36
37
38 2008;39(3):760-7. doi: 10.1161/STROKEAHA.107.494823. Epub 2008 Jan 31.
39 PubMed PMID: 18239177.

40
41
42
43
44
45 8. Hozawa A, Okamura T, Kadowaki T, Murakami Y, Nakamura K, Hayakawa T, Kita
46 Y, Nakamura Y, Okayama A; Hirotsugu Ueshima for NIPPON DATA80 Research
47 group. Is weak association between cigarette smoking and cardiovascular disease
48 mortality observed in Japan explained by low total cholesterol? NIPPON DATA80. *Int*
49
50
51
52
53
54
55
56
57
58
59
60
J Epidemiol. 2007 Oct;36(5):1060-7. Epub 2007 Sep 10. PubMed PMID: 17846054.

- 1
2
3
4 9. Nakamura K, Barzi F, Huxley R, Lam TH, Suh I, Woo J, Kim HC, Feigin VL, Gu D,
5
6 Woodward M; Asia Pacific Cohort Studies Collaboration. Does cigarette smoking
7
8 exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the
9
10 risk of cardiovascular diseases? *Heart*. 2009;95(11):909-16. doi:
11
12 10.1136/hrt.2008.147066. Epub 2009 Feb 5. PubMed PMID: 19196734.
13
14
15
16 10. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular
17
18 disease in men with low levels of serum cholesterol: the Korea Medical Insurance
19
20 Corporation Study. *JAMA*. 1999;282(22):2149-55.
21
22
23
24 11. Jee SH, Park J, Jo I, Lee J, Yun S, Yun JE, Jang Y. Smoking and atherosclerotic
25
26 cardiovascular disease in women with lower levels of serum cholesterol.
27
28 *Atherosclerosis*. 2007;190(2):306-12. Epub 2006 May 4.
29
30
31
32 12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones
33
34 DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and
35
36 Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and
37
38 Treatment of High Blood Pressure; National High Blood Pressure Education Program
39
40 Coordinating Committee. The Seventh Report of the Joint National Committee on
41
42 Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7
43
44 report. *JAMA*. 2003;289(19):2560-72. Epub 2003 May 14. Erratum in: *JAMA*. 2003 Jul
45
46 9;290(2):197. PubMed PMID: 12748199.
47
48
49
50
51 13. The National Cholesterol Education Program. Report of the Expert Panel on Blood
52
53 Cholesterol Levels in Children and Adolescents. NIH Publication No. 91-2732.
54
55
56 Bethesda, MD; 1994.
57
58
59
60

- 1
2
3
4 14. National Diabetes Data Group. Report of the Expert Committee on the Diagnostic
5 Classification of Diabetes. *Diabetes Care*. 1997;20(7):1183–97.
6
7
8
9
10 15. Kimm H, Yun JE, Lee SH, et al. Validity of the diagnosis of acute myocardial
11 infarction in Korean national medical health insurance claims data: the Korean Heart
12 Study (1). *Korean Circ J* 2012;42:10–15.
13
14
15
16
17 16. Kim HY. Validity of the diagnosis of acute myocardial infarction in Korean
18 national medical health insurance claims data: the Korean Heart Study [Master thesis].
19 Yonsei University, Seoul, Korea, June 2013.
20
21
22
23
24
25 17. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1: The analysis
26 of case-control studies. Lyon, France: IARC Scientific Publication No. 32, pp. 146–50.
27
28
29
30 18. Levin ML. The occurrence of lung cancer in man. *Acta Intern Cancer* 1953;19:531.
31
32
33
34 19. Thut AB, Blizzard L, Schmidt MD, Luc PH, Granger RH, Dwyer T. The association
35 between smoking and hypertension in a population-based sample of Vietnamese men. *J*
36 *Hypertens*. 2010; 28: 245 – 50.
37
38
39
40
41 20. Kim BJ, Seo DC, Kim BS, Kang JH. Relationship between cotinine-verified
42 smoking status and incidence of hypertension in 74,743 Korean adults. *Circ J*. 2018 Feb
43 28. doi: 10.1253/circj.CJ-17-1188. [Epub ahead of print].
44
45
46
47
48
49 21. Morotti E, Battaglia B, Fabbri R, Paradisi R, Venturoli S, Battaglia C. Cigarette
50 smoking and cardiovascular risk in young women with polycystic ovary syndrome. *Int*
51 *J Fertil Steril*. 2014;7(4):301-12. Epub 2013 Dec 22.
52
53
54
55
56
57 22. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the

1
2
3
4 general population in Japan. *J Hypertens* 1990;8(Suppl 5):S9–S15.

5
6
7 23. Fujishima M, Kiyohara Y, Ueda K, Hasuo Y, Kato I, Iwamoto H. Smoking as
8 cardiovascular risk factor in low cholesterol population: the Hisayama Study. *Clin Exp*
9
10
11
12 *Hypertens A*. 1992;14(1-2):99-108.

13
14
15 24. Gordon T, Garcia-Palmier MR, Kagan A, Kannel WB, Schiffman J. Differences in
16 coronary heart disease in Framingham, Honolulu and Puerto Rico. *J Chronic Dis*.
17
18
19
20
21 1974;27:329–44.

22
23 25. Thun, M. J., Day-Lally, C., Myers, D. G., Calle, E. E., Flanders, W., Zhu, B., ... &
24 Heath, C. W. (1982). Trends in tobacco smoking and mortality from cigarette use in
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). National
Cancer institute, smoking and tobacco control, monograph, 8.

26. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking
cessation in relation to mortality in women. *JAMA*. 2008;299(17):2037-47.

27. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking
cessation: myocardial infarction and stroke. *Circulation*. 1997;96(4):1089-96.

28. Bernaards CM1, Twisk JW, Snel J, van Mechelen W, Kemper HC. In a prospective
study in young people, associations between changes in smoking behavior and risk
factors for cardiovascular disease were complex. *J Clin Epidemiol*. 2005
Nov;58(11):1165-71.

29. Murtaugh KH, Borde-Perry WC, Campbell KL, Gidding SS, Falkner B. Obesity,
smoking, and multiple cardiovascular risk factors in young adult African Americans.

1
2
3
4 *Ethn Dis.* 2002 Summer;12(3):331-5.
5
6

7 30. West HW, Juonala M, Gall SL, Kähönen M, Laitinen T, Taittonen L, Viikari JS,
8 aitakari OT, Magnussen CG. Exposure to parental smoking in childhood is associated
9 with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular
10 Risk in Young Finns Study. *Circulation.* 2015 Apr 7;131(14):1239-46. doi:
11 10.1161/CIRCULATIONAHA.114.013485. Epub 2015 Mar 23.
12
13

14 31. Roy MP, Steptoe A, Kirschbaum C. Association between smoking status and
15 cardiovascular and cortisol stress responsivity in healthy young men. *Int J Behav Med.*
16 1994;1(3):264-83.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Figure legends**

41
42
43 Figure 1. Timeline for data collection in the Korean Life Course Health Study
44
45
46
47

48
49 Figure 2. Survival of atherosclerotic cardiovascular disease event by smoking history in
50 Korean young adult men, 1992-2015
51
52
53
54
55

56
57 Figure 3. Hazard ratios with 95% confidence intervals for from ischemic heart disease,
58
59
60

1
2
3
4 and stroke by cigarette per day and duration of smoking
5
6
7
8
9

10 Figure 4. Hazard ratios with 95% confidence intervals for ischemic heart disease and
11 stroke by total cholesterol groups of smokers compared with nonsmokers: Each group
12 of total cholesterol levels are as follows: first, 149 mg/dl; second, 150-169 mg/dL; third,
13 170-194 mg/dL; fourth, ≥ 195 mg/dL. The reference group is non-smokers in each
14 quartile of total cholesterol.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline Characteristics of the Korean Life Course Health Study, 1992-1994, According to Smoking Status*

Characteristic	Nonsmokers (n=24,950)	Ex-smokers (n=15,126)	No. of cigarettes per day among current smokers			P for Trend†‡
			1-9 (n=22,642)	10-19 (n=35,690)	≥20 (n=20,123)	
Age, year	26.6 (2.1)	26.9 (1.9)	26.6 (2.0)	26.8 (1.9)	26.8 (1.9)	0.1622
Systolic Blood Pressure, mmHg	120.4 (11.6)	120.0 (11.8)	119.8 (11.6)	120.1 (11.6)	120.3 (11.6)	0.2558
Diastolic Blood Pressure mmHg	78.0 (9.0)	77.7 (9.1)	77.5 (9.0)	77.8 (9.0)	78.0 (9.0)	0.1122
Total cholesterol, mg/dL	173.4 (32.9)	173.4 (32.6)	172.9 (33.1)	174.5 (33.4)	177.2 (34.4)	0.9543
Body mass index, kg/m ²	22.3 (2.4)	22.4 (2.4)	22.3 (2.4)	22.5 (2.5)	22.9 (2.6)	0.0056
Fasting serum glucose, mg/dL	86.7 (13.3)	86.6 (13.5)	86.2 (14.1)	86.4 (14.1)	86.6 (15.3)	0.4821
Alcohol consumption, g per day	7.3 (17.7)	9.7 (19.7)	12.2 (22.6)	14.5 (25.1)	20.4 (36.1)	<.0001
Conditions, %						
Hypertension†	15.7	15.1	14.5	15.6	15.7	0.7987
Hypercholesterolemia‡	3.4	3.3	3.3	3.9	4.7	0.0743
Diabetes§	0.7	0.8	0.9	0.9	1.0	0.0060
Alcohol use	61.2	81.3	88.2	88.3	86.9	0.1035
Physical activity	24.9	26.8	22.9	17.5	13.0	<.0001

*Data are expressed as means (SD) unless otherwise indicated; †Systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least

1
2
3 90 mmHg; ‡Total cholesterol level of at least 6.21 mmol/L (240 mg/dL); § Fasting serum glucose value of at least 6.99 mmol/L (126 mg/L); || Consumption
4 of Soju which is a colorless distilled beverage of Korean origin; ¶¶Testing for trend across nonsmokers and current smokers; ex-smokers were excluded.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Table 2. Risk of Morbidity from Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men in the Korean Life Course Health Study, 1992-2015*

Variables and Categories	Ischemic Heart Disease		Cerebrovascular Disease		Atherosclerotic Cardiovascular Disease	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age (5-year age group)	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.3 (1.2 – 1.4)	<.0001
Cigarette smoking						
Ex-smoker	1.0 (0.9 – 1.2)	0.8567	1.1 (0.9 – 1.3)	0.5008	1.1 (1.0 – 1.2)	0.1406
Current smoker	1.5 (1.3 – 1.6)	<.0001	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
Blood Pressure†						
High normal	1.2 (1.1 – 1.4)	<.0001	1.2 (1.0 – 1.3)	0.0152	1.2 (1.1 – 1.3)	<.0001
Stage 1 hypertension	1.6 (1.4 – 1.8)	<.0001	1.7 (1.5 – 2.0)	<.0001	1.7 (1.5 – 1.8)	<.0001
Stage 2 hypertension	2.0 (1.6 – 2.5)	<.0001	3.2 (2.5 – 4.0)	<.0001	2.9 (2.5 – 3.3)	<.0001
Total cholesterol‡						
Borderline-high cholesterol	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
High cholesterol	2.5 (2.1 – 2.8)	<.0001	1.7 (1.4 – 2.1)	<.0001	2.1 (1.8 – 2.3)	<.0001
Fasting blood sugar§						
Diabetes	1.3 (0.9 – 1.9)	0.1375	1.6 (1.1 – 2.3)	0.0222	1.5 (1.2 – 1.9)	0.0008
Physical activity						
No exercise	1.1 (1.0 – 1.3)	0.0122	1.1 (1.0 – 1.3)	0.2156	1.1 (1.0 – 1.3)	0.0075

*Hazard ratio (HRs) and 95% confidence intervals (CIs) from multivariable Cox proportional hazards models. †The reference category is normal (systolic

1
2
3 blood pressure<140 mmHg and diastolic blood pressure<90mm Hg). ‡ The reference category is desirable (serum cholesterol level, < 5.17 mmol/L [200
4 mg/dL]). §The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only


Table 3. Population Attributable Risks (PARs) and 95% Confidence Intervals (CIs) From Smoking and Other Risk Factors of Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men: The Korean Life Course Health Study

Variables and Categories	Prevalence %	Ischemic Heart Disease PAR (95% CI)	Cerebrovascular Disease PAR (95% CI)	Atherosclerotic Cardiovascular Disease PAR (95% CI)
Smoking				
Current smoker	66.2	24.9 (16.6 – 28.4)	20.9 (11.7 -28.4)	20.9 (16.5 – 24.9)
Blood Pressure*				
Hypertension	22.0	8.1 (6.2 – 9.9)	13.3 (9.9 – 14.9)	9.9 (9.9 – 11.7)
Total cholesterol†				
Borderline	16.6	6.2 (4.7 – 9.1)	6.2 (4.7 – 7.7)	6.2 (4.7 – 7.6)
High	3.8	5.4 (4.0 – 6.4)	4.0 (2.9 – 4.7)	4.0 (2.9 – 4.7)
Fasting blood sugar‡				
Diabetes	0.9	0.3 (-0.9 – 0.8)	0.5 (0.08 – 1.1)	0.4 (0.2 – 0.8)
Physical activity				
No exercise	0.8	7.4 (0 – 19.3)	7.4 (0 – 19.3)	7.4 (0 – 19.3)

*The reference category is normal (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90mm Hg). †The reference category is desirable (serum cholesterol level < 5.17 mmol/L [200 mg/dL]). ‡ The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



69x33mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2


254x190mm (300 x 300 DPI)

Figure 3.


A. Ischemic Heart Disease




B. Ischemic Heart Disease




C. Stroke




D. Stroke



E. ASCVD




F. ASCVD



46x53mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.



46x94mm (300 x 300 DPI)

Title: smoking is the first leading cause of cardiovascular disease in Young Men.

STROBE Statement—Checklist of items that should be included in reports of cohort studies

	Item No	Recommendation
Title and abstract	①	(a) Indicate the study's design with a commonly used term in the title or the abstract <i>Page 3</i> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <i>page 3</i>
Introduction		
Background/rationale	②	Explain the scientific background and rationale for the investigation being reported <i>page 5</i>
Objectives	③	State specific objectives, including any prespecified hypotheses <i>page 6, para 1.</i>
Methods		
Study design	④	Present key elements of study design early in the paper <i>Page 6, para 2</i>
Setting	⑤	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <i>page 6-7.</i>
Participants	⑥	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>page 6, page 8</i> (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	⑦	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <i>page 7, para 3, page 8</i>
Data sources/ measurement	⑧*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <i>page 6, page 7</i>
Bias	⑨	Describe any efforts to address potential sources of bias <i>page 14.</i>
Study size	⑩	Explain how the study size was arrived at <i>page 7</i>
Quantitative variables	⑪	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>page 8</i>
Statistical methods	⑫	(a) Describe all statistical methods, including those used to control for confounding <i>page 9</i> (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed <i>page 8</i> (e) Describe any sensitivity analyses <i>page 9-10</i>
Results		
Participants	⑬*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <i>page 10</i> (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram <i>page 7. (Figure 1)</i>
Descriptive data	⑭*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <i>page 10</i> (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) <i>page 10 (23 years of follow-up)</i>
Outcome data	⑮*	Report numbers of outcome events or summary measures over time <i>page 10.</i>
Main results	⑯	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <i>page 10, para 1 (Table 2)</i> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	page 11 (Figure 4)
2	Discussion			
3	Key results	18	Summarise key results with reference to study objectives	page 12 para 2
4	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 14, para 2.
5	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 14
6	Generalisability	21	Discuss the generalisability (external validity) of the study results	page 14
7	Other information			
8	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean Life Course Health Study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024453.R3
Article Type:	Research
Date Submitted by the Author:	16-Feb-2019
Complete List of Authors:	Jee, Yongho; Seoul National University, Department of Public Health Jung, Keum Ji; Yonsei University Graduate School Institute for Health Promotion, Dept. of Public Health Lee, Sunmi; National Health Insurance Service, Health Insurance Policy Research Institute Back, Joung Hwan; Health Insurance Policy Research Institute Jee, Sun Ha; Graduate School of Public Health, Yonsei University, Epidemiology Cho, Sung-il ; Seoul National University, Department of Public Health
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Smoking and tobacco, Public health, Cardiovascular medicine
Keywords:	Smoking, Cardiovascular Disease, Young adults

SCHOLARONE™
Manuscripts

1
2
3
4 Smoking and Atherosclerotic Cardiovascular Disease Risk in Young Men: The Korean
5
6 Life Course Health Study
7
8
9

10
11 Yongho Jee, MPH^{1,2}, Keum Ji Jung, PhD^{2,4}, Sunmi Lee, PhD³, Joung Hwan Back, PhD³,
12
13 Sun Ha Jee, PhD^{2,4*}, Sung-il Cho, MD, PhD^{1*}
14
15

16
17
18 ¹ Department of Public Health Science, Graduate School of Public Health, Seoul
19
20 National University, Seoul, Republic of Korea
21
22

23 ² Institute for Health Promotion, Graduate School of Public Health, Yonsei University,
24
25 Seoul, Republic of Korea
26
27

28
29 ³ Health Insurance Policy Research Institute, Wonju, Republic of Korea
30
31

32 ⁴ Department of Epidemiology and Health Promotion, Graduate School of Public Health,
33
34 Yonsei University, Seoul, Republic of Korea
35
36

37
38
39
40 Running title: Smoking and Atherosclerotic Cardiovascular Disease
41
42
43
44
45

46 *These last authors contributed equally to this work
47
48

49 *Corresponding authors.
50

51 Department of Public Health Science, Graduate School of Public Health, Seoul
52
53 National University, Seoul, Republic of Korea
54
55

56
57 E-mail address: scho@snu.ac.kr (S.I. Cho).
58

1
2
3
4 Department of Epidemiology and Health Promotion, Graduate School of Public Health,
5
6 Yonsei University, Seoul, Republic of Korea.
7

8
9 E-mail address: jsunha@yuhs.ac (S.H. Jee).
10

11 These two authors equally contributed as corresponding author.
12
13
14

15
16 Word count: 3,048
17

18 Table 3, Figure 4
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Abstract

Objective: To examine the effect of smoking on risk of atherosclerotic cardiovascular disease (ASCVD) in Korean young men and to examine whether serum total cholesterol levels could modify the effect of smoking on ASCVD.

Design: A prospective cohort study within a national insurance system.

Setting: Health screenings provided by national insurance in 1992 and 1994.

Participants: 118,531 young men between 20 and 29 years of age and were followed up for an average of 23 years.

Outcome measure: To assess the independent effects of smoking on the risk of Ischemic Heart Disease (IHD), stroke, and ASCVD, Cox proportional hazards regression models were used, controlling for age, hypertension, diabetes, hypercholesterolemia, and alcohol drinking.

Results: The total number of current smokers was 78,455 (66.2%), and 94,113 (79.7%) of the sample recorded a total cholesterol level < 200 mg/dl measured at baseline. Between 1993 and 2015, 2,786 cases of IHD (53/100,000 person year), 2,368 cases of stroke (45.4/100,000 person year), and 6,368 ASCVD (122.7/100,000 person year) occurred. The risk of IHD, stroke, and total ASCVD events was found to increase for current smokers, with a hazard ratios (HR) with 95% Confidence Interval (CI) of 1.5 (95% CI: 1.3,1.6), 1.4 (95% CI: 1.2,1.6), and 1.4 (95% CI: 1.3,1.5), respectively. Further, the risks above were also found throughout the range of serum levels of cholesterol.

1
2
3
4 **Conclusions:** Smoking among Korean young adult men was independently associated
5
6 with increased risk of IHD, stroke and ASCVD. The concentration of cholesterol in
7
8 Korean men did not modify the effect of smoking on ASCVD.
9

10
11
12 **Keywords:** Smoking, Cardiovascular Disease, Young adults
13
14
15
16
17
18
19
20
21
22
23

24 **Strengths and limitations of this study**

- 25
26
27 ▪ Novel result from Korean young adults is that smoking is the first leading cause of
28
29 Cardiovascular Disease (CVD) while smoking is the second leading cause of CVD in
30
31 middle aged adults.
32
- 33
34
35 ▪ The large sample size of cohort with 118,531 young men between 20 and 29 years of
36
37 age and were followed up for an average of 23 years.
38
- 39
40
41 ▪ The limitations of this study include possible measurement errors and the non-random
42
43 sample used.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Atherosclerotic cardiovascular diseases (ASCVD) are the leading cause of death globally, with more people dying from ASCVD than any other causes of death annually. A total of 17.7 million people died as a result of ASCVDs in 2015 globally, comprising 31% of all deaths. Of these deaths, 7.4 million are estimated to have been the result of coronary heart disease, whilst 6.7 million were due to stroke¹. According to previous studies published in the western countries, tobacco use has been reported to be a major risk factor for ASCVD following hypertension.¹

A growing concern is that for young adults, cigarette smoking may be the first leading cause of ASCVD, owing to the high prevalence of cigarette smoking in comparison to lower levels of alternate risk factors, including hypertension, diabetes, and high cholesterol levels. However, despite these observations, there remain only a small number of studies considering the relationship between smoking and ASCVD in Korea and other countries in East Asia.²⁻⁵

Further, comparisons with Western populations may be less informative owing to the relatively lower levels of cholesterol commonly present in Asian countries. Biological studies have explored the interaction between smoking and serum cholesterol levels.⁶⁻⁹ Nevertheless, very few studies have analyzed the interaction effects of smoking and serum cholesterol on ASCVD in young adults

‘World No Tobacco Day 2018’ is a campaign, with the primary objective of raising awareness of the link between tobacco use and negative health outcomes, predominantly heart and other cardiovascular diseases (CVD) including stroke. It will

1
2
3
4 also seek to expand the range of potential strategies key public actors such as
5
6 governmental and public bodies can take to reduce the health risks of tobacco use. If
7
8 there is an established link between tobacco smoking in young adults and CVD, the
9
10 campaign will further increase awareness on smoking in young adults. The government
11
12 and the public can then subsequently take actions to reduce risks of smoking at earlier
13
14 stage. Unfortunately, however, the association between smoking and CVD in young
15
16 adults has not received much attention because at least a long term (over 20 years)
17
18 follow-up study is needed. This serves as motivation for this study, in which we aimed
19
20 to examine the effect of smoking on risk of ASCVD in Korean young adults with
21
22 relatively low serum cholesterol levels. We also investigated whether the effect of
23
24 smoking can be modified by serum levels of cholesterol.
25
26
27
28
29
30
31
32

33 **METHOD**

34 **Study participants**

35
36
37
38 In Korea, the Korean Medical Insurance Corporation (KMIC) provided health insurance
39
40 for private school staff and civil servants prior to the current insurance system, under
41
42 which it was integrated as National Health Insurance.² A total of 4,862,438 (10.7%) of
43
44 the Korean population were covered by KMIC insurance, of which 1,297,833 were
45
46 employees, and 3,364,605 were dependents. All insured participants are required to
47
48 participate in a biennial health checkup.² Approximately 94% of the insured participants
49
50 in 1992 and 1994 were examined biennially. We established a prospective cohort for
51
52 participants (aged 20-29) who routinely responded to the questionnaire on disease risk
53
54
55
56
57
58
59
60

1
2
3
4 factors and chronic diseases, naming this study the Korean Life Course Health Study
5 (KLCHS). The KLCHS cohort included 307,041 Koreans (142,461 males, 164,580
6
7 females) who were screened by KMIC in 1992 and 1994. Of these participants, 205,840
8
9 (67.0%) were registered in 1992 and 101,201 (33.0%) were registered in 1994.
10
11
12

13
14 Of these 307,041 participants, 71,760 (23.4%) who had incomplete data height, blood
15
16 pressure, fasting glucose, total cholesterol, or body mass index were excluded. We also
17
18 excluded 6,170 people from our analysis who reported a past history of cancer and
19
20 ASCVD, as well as 2,091 people who had missing information on smoking, exercise, or
21
22 alcohol drinking, and 65 people who died before start of follow-up. Female participants
23
24 were excluded, because of the low prevalence of smoking for females in Korea,
25
26 resulting in a total of 118,531 eligible participants for the analysis. The study proposal
27
28 obtained an approval by the Institutional Review Board of Human Research, Yonsei
29
30 University (4-2001-0029) and the Seoul National University (E1812/001-010). This
31
32 study was a retrospective cohort using past routine laboratory data and did not receive
33
34 consent.
35
36
37
38
39
40
41
42
43

44 **Data collection**

45
46 The biennial KMIC screening was provided at local hospitals by medical practitioners
47
48 according to standard protocols. During the two-year interval examination from 1992 to
49
50 2008, we examined the variables related to the lifestyle of participants, such as daily
51
52 smoking amount, duration of smoking, and variables related to drinking. From data
53
54 collected at baseline, participants were defined as 'current smokers' if they were
55
56
57
58
59
60

1
2
3
4 smoking currently, 'never smokers' if they had no prior history of smoking, and 'ex-
5 smokers' if they had previously smoked but at the time of measurement did not smoke.
6
7
8
9 Current smokers were further categorized by amount of cigarettes consumed on average
10
11 per day (1–9, 10–19, and 20 or greater) as well as duration of smoking (1–9, 10–19, and
12
13 20 or more years) following the example of previous studies.^{2,10,11}
14

15
16 The definition of hypertension was a systolic BP \geq 140 mmHg or diastolic BP \geq 90
17
18 mmHg.¹² Body mass index (BMI) was measured as weight (kg) / height (m)². Serum
19
20 total cholesterol was grouped as desirable (<200 mg/dl), borderline-high (200-239
21
22 mg/dl), and high (\geq 240 mg/dl).¹³ Definition of diabetes was fasting blood glucose \geq
23
24
25
26
27 126 mg / dl.¹⁴
28
29
30
31
32

33 **Follow-up and outcomes**

34
35
36 The main outcome variables used in the analysis were morbidity and mortality
37
38 categorized by IHD, stroke, and ASCVD. For IHD, alone (ICD 10 codes, I20–I25),
39
40 acute myocardial infarction (AMI) alone (I21), and angina pectoris (AP) alone (ICD 10
41
42 codes, I20) are used. For stroke, stroke alone (I60–I69) was used. Finally, with regard to
43
44 ASCVD, we used total ASCVD, including disease of hypertensive (I10–I15), ischemic
45
46 heart disease (I20–I25), all stroke (I60–I69), other heart disease (I44–I51), sudden death
47
48 (R96), and other vascular disease (I70–I74).
49
50
51
52

53 The study outcomes were identified through diagnosis information recorded in hospital
54
55 admission, and from causes of death using death certificates. The study follow-up was
56
57
58
59
60

1
2
3
4 nearly 100% complete, as we were able to search ASCVD event data electronically by
5
6 KMIC registrants regarding the morbidity information of ASCVD. The period of
7
8 follow-up was 23 years from January 1st, 1993 to December 31st, 2015. Data on causes
9
10 of death were available during years 1993–2015, and incidence could be tracked during
11
12 years 1995–2015. The time frames over which these outcomes could be assessed varied
13
14 with data availability (Figure 1).
15
16

17
18 A validation study was conducted by 20 internists from the Korean Society of
19
20 Cardiology in 2009.¹⁵ For the participants who provided written permission for the use
21
22 of their personal information, 673 CHD events between 1994 and 2007 were confirmed
23
24 with individual hospital medical records, showing that 73% of designated myocardial
25
26 infarctions were valid. The validation study was updated in 2013 with a value of 93%.¹⁶
27
28 The validation study on mortality data has not been conducted.
29
30
31
32
33
34
35
36

37 **Statistical analysis**

38
39 First, we examined relationships between smoking status and established ASCVD risk
40
41 factors at baseline. In considering continuous ASCVD risk factors, we used ordinary
42
43 least squares regression and coded smoking quantity as an ordinal variable. In this study,
44
45 the Mantel Haenszel method was applied for dichotomous variables.¹⁷
46
47
48

49 To assess the independent effects of smoking on the risk of IHD, stroke, and ASCVD,
50
51 Cox proportional hazards models were used, controlling for age and the confounding
52
53 variables such as hypertension, diabetes, high cholesterol, and alcohol drinking. The
54
55 proportional assumption was also tested utilizing Schoenfeld residuals, and the survival
56
57
58

1
2
3
4 curve according to smoking status was plotted using the life-table method. We used
5
6 Levins formula for calculating population attributable risk (PAR).¹⁸ In additional
7
8 analyses, we excluded all events that had occurred in the first 4 years of follow-up.
9
10 These analyses ensured sensitivity in our results. In all analyses, a two-sided
11
12 significance level of 0.05 was used.
13
14
15
16
17
18
19

20 **Patient and Public Involvement**

21
22 Patients and or public were not involved.
23
24
25
26
27
28
29

30 **RESULTS**

31
32 The average age of the study participants was 26.7 ± 2.0 (SD) years. Among the
33
34 118,531 men, 78,455 (66.2%) were current smokers, 15,126 (12.8%) were ex-smokers,
35
36 and 92,403 (15.4) had hypertension. For total cholesterol, 94,413 (79.7%) had a total
37
38 serum cholesterol level < 200 mg/dL, 19,764 (16.6%) had a borderline level of 200-240
39
40 mg/dL, and 4,444 (3.8%) had a level of 240 mg/dL or higher. In terms of amount of
41
42 smoking, 28.9% smoked more than 20 cigarettes per day while 45.5% and 25.6% of
43
44 current smokers smoked 1 to 9 and 10 to 19 cigarettes per day, respectively. Among
45
46 current smokers, 92.0% smoked for less than 10 years while 7.6% and 0.4% of current
47
48 smokers smoked for 10 to 19 years and more than 20 years, respectively.
49
50
51
52
53

54 Population characteristics by smoking status are presented in Table 1. After adjusting
55
56 for age, current smokers had a significantly higher body mass index (P for trend =
57
58
59
60

0.0056), higher consumption of alcohol drinking (P for trend <.0001), and higher prevalence of diabetes (P for trend = 0.0060) than nonsmokers.

The mean length of follow-up was 23 years, for a total of 5,191,823 person-years. During this period, 2,786 (90 fatal) IHD cases (53/100,000 person year), stroke cases 2,368 (126 fatal) (45.4/100,000 person year), and 6,368 ASCVD cases (306 fatal) (122.7/100,000 person year) occurred

The independent effects of smoking on IHD, stroke, and ASCVD were analyzed controlling for confounding factors through Cox proportional hazards models, as shown in Table 2. The hazard ratios (HR) relating to IHD for current smokers were 1.5 (P <.0001), and those of ex-smokers were 1.0 (P=0.8567). The HR of stroke was 1.4 (P <.0001) for current smokers and 1.1 (P = 0.5008) on ex-smokers.

Compared to nonsmokers, the HR for any ASCVD event was 1.4 (P < 0.0001) in current smokers and 1.1 in ex-smokers (P = 0.1406). Figure 2 shows the survival probability by smoking history (never, former, 1-9, 10-19, ≥ 20 cigarette per day among current smokers) and the corresponding unadjusted association with ASCVD. The overall results demonstrated that smoking among young men increased the risk for ASCVD relative to nonsmokers. After adjusting for age and traditional ASCVD risk factors, the HRs for IHD and stroke were estimated for groups classified by amount of smoking (A and B in Figure 3) and duration of smoking (C and D in Figure 3). For IHD and stroke, the risk of events increased linearly with higher amount of cigarette per day (P for trend, <.0001 and <.0001, respectively) and longer duration of smoking (P for trend, <.0001 and <.0001, respectively).

1
2
3
4 To examine whether serum total cholesterol levels could modify the effect of smoking
5 on ASCVD, we divided the cohort participants into quartile of total cholesterol. The
6 risks above were also found throughout the range of serum levels of cholesterol
7 demonstrating that serum total cholesterol levels did not modify the effect of smoking
8 on ASCVD (Figure 4).
9
10
11
12
13
14

15
16 Estimated risk factor prevalence in current studies of smoking and other additional risk
17 factors were used to estimate the PARs for IHD alone, stroke alone and total ASCVD
18 (Table 3). For IHD, current smoking accounts for about 24.9% of events, and
19 hypertension accounts for 8.1% of events. In the case of stroke, smoking was estimated
20 to account for 20.9%, whilst hypertension was estimated to be responsible for 13.3% of
21 stroke cases.
22
23
24
25
26
27
28
29
30
31
32
33

34 **DISCUSSION**

35
36 Our study investigated the association between smoking and risk of ASCVD among
37 Korean young men within a cohort study with a 23 year of follow-up. To our
38 knowledge, this is the first study focusing on Korean young adults. In our study,
39 smoking was the most crucial risk factor attributing to 20% of ASCVD mortality in
40 middle age.
41
42
43
44
45
46
47
48

49 Diabetes, hypertension, and hyperlipidemia are well known risk factors for ASCVD¹⁰.
50 However, for young adults with relatively low incidence of diabetes, hypertension and
51 hyperlipidemia, smoking is the most important and an independent risk factor for
52 predicting ASCVD in the present study. Furthermore, the high smoking rate among
53
54
55
56
57
58
59
60

1
2
3
4 young people is important with respect to the development of middle-aged hypertension
5
6 and transition to ASCVD.¹⁹⁻²⁰ Thus, middle-aged ASCVD morbidity is likely
7
8 predominantly predicted by smoking in young adulthood.
9

10
11
12 The body of research centered upon the health effects of smoking is steadily increasing,
13
14 with findings reported from many countries around the world. However, few studies
15
16 have examined the effect of smoking on ASCVD in young adults.²¹ Here, we present
17
18 evidence that current smoking is an independent risk factor affecting the incidence of
19
20 IHD, stroke and ASCVD.
21
22

23
24 These risk associations have been estimated across total serum cholesterol groups. A
25
26 cohort study in Hasayama Japan found that smoking showed positive association with
27
28 coronary heart disease in people with high levels of serum cholesterol above 180 mg /
29
30 dl, but not with people with low level of cholesterol less than 180 mg / dl.²²⁻²³
31
32 Afterward, six epidemiological studies were conducted. Among them, one study from
33
34 Puerto Rico Heart Health Program²⁴ showed similar results, but not all.⁷⁻¹¹ Of course,
35
36 all studies were conducted among adult populations. To the best of our knowledge, no
37
38 study has been done on young adults with much lower levels of serum cholesterol. In
39
40 addition, the high smoking rate among young adults is likely to be, even directly, linked
41
42 to high blood pressure among the adult population who developed ASCVD as a major
43
44 health problem.
45
46
47
48
49

50
51 In this study, the non-significant risk of ASCVD among ex-smokers can be interpreted
52
53 in two ways. First, this result may simply reflect the effect of smoking cessation. Most
54
55 previous studies have shown that the effects of smoking cessation are immediate in
56
57 CVD (most of the excess risk of vascular mortality due to smoking may be eliminated
58
59 rapidly upon cessation), while lung cancer occurs within 20 years^{25, 26}. In particular,
60
most of the excess risk of vascular mortality due to smoking in women may be

1
2
3
4 eliminated rapidly upon cessation and within 20 years for lung diseases.²⁶ Second,
5 even if a number of young adult ex-smokers, aged 20-29 years, may have smoked
6 continuously from adolescence, it is still a short term of smoking, compared to adults.
7 Previous study shown that reducing adult smoking pays more immediate dividends,
8 both in terms of health improvements and cost savings.²⁷ While present study lacks
9 information on smoking duration of ex-smokers, current smokers who continued to
10 smoke seem to have increased risk of CVD by 40%. Therefore, while the smoking
11 duration of ex-smokers is unknown, it may be reasonable to consider the results were
12 mainly affected by the smoking cessation. Further research on the effects of smoking
13 cessation among young adults is necessary.
14
15
16
17

18 There are several studies regarding cardiovascular risk among young people. According
19 to a study conducted by Bernaards et al.,²⁸ blood pressure and waist circumference were
20 decreased by lowering weekly tobacco consumption in younger participants. However,
21 they did not report the risk of developing cardiovascular disease events due to changes
22 in smoking. This seems to be another significant topic relating to the health of young
23 adults. Another study conducted by Morotti et al.²¹ on young women with polycystic
24 ovary syndrome (PCOS) reported an association between smoking habitude in lean
25 PCOS patients, and the increase of soft markers of cardiovascular risk. For young adult
26 African Americans, the association between cigarette smoking and carotid intima
27 assuming the genetic variation of smokers was reported and the -930^{A/G} polymorphism
28 modified the association among young healthy adults.²⁹ The study on association
29 between second hand smoking among childhood and cardiovascular event in adulthood
30 was conducted and found that the carotid plaque risk in adulthood is increased in
31 children whose parents had smoked.³⁰⁻³¹
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50
51 This LCHS study has several strengths, such as high follow-up rates and a large,
52 national sample. The large sample size of cohort allowed us to investigate the
53 association of smoking with various levels of serum cholesterol. The civil servants and
54
55
56
57

1
2
3
4 private school teachers who participated in this study accounted for about 11% of the
5 total population in 1992. We did not compare the characteristics of the 89% population
6 not included in the study. Therefore, this study will not represent the whole population.
7
8 Moreover, selection bias may be a potential issue, since the final sample contains a
9 subset of over 118,531 young male adults (38.6%) out of 307,041 subjects initially
10 selected for our study. We therefore urge conservative interpretations of our study
11 results with regard to the general population.
12
13
14
15
16
17
18
19
20

21 In conclusion, smoking is a leading cause of ASCVD among young adults in Korea, a
22 country with a low total cholesterol level and a high smoking rate. Moreover, the
23 association was not modified by total cholesterol level. Smoking among Korean young
24 adult men was independently associated with increased risk of IHD, stroke and ASCVD.
25
26 The concentration of cholesterol in Korean men did not modify the effect of smoking
27 on ASCVD. Therefore, smoking cessation on young adult smokers is essential to
28 prevent CVD later in adult life. Moreover, clinical practice guidelines and policies
29 should emphasize to treat nicotine addiction in young smokers.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 **Acknowledgments:** We appreciate the assistance of the Korean National Health
53 Insurance Service, which provided the data for this study.
54
55
56
57
58
59
60

52 **Contributors:** Data analysis was undertaken by YJ and KJJ. The article was drafted by
53 YJ. SL, JHB, SHJ, and SC substantially contributed to the conception or design of the
54 work, revising the work, approved the final version to be published, and agreed to be
55
56
57
58
59
60

1
2
3
4 accountable for all aspects of the work in ensuring that questions related to the accuracy
5
6 or integrity of any part of the work are appropriately investigated and resolved.
7
8
9
10
11

12
13 **Funding Sources:** This study was funded with a grant from the Korean Health
14
15 Technology R&D Project, Ministry of Health & Welfare, Republic of Korea
16
17 (HI14C2686). The funder had no role in the study design and data collection, in
18
19 analyzing and interpreting data, or in the decision to submit this work for publication
20
21
22
23
24

25 **Conflict of interests:** None declared
26
27
28
29
30

31 **Ethics approval:** The study proposal obtained an approval by the Institutional Review
32
33 Board of Human Research, Yonsei University (4-2001-0029).
34
35
36

37 **Provenance and peer review:** Not commissioned; externally peer reviewed.
38
39
40

41 **Data sharing statement:** No additional data are available.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). Fact sheet. Updated May 2017. <http://www.who.int/mediacentre/factsheets/fs317/en/>. Visited at 3 March, 2018.
2. Jee SH, Samet JM, Ohrr H, Kim JH, Kim IS. Smoking and cancer risk in Korean men and women. *Cancer Causes Control*. 2004;15(4):341-8.
3. Yuan JM, Ross RK, Wang XL, Gao YT, Henderson BE, Yu MC. Morbidity and mortality in relation to cigarette smoking in Shanghai, China. *JAMA* 1996: 1646–50.
4. Liu B-Q, Peto R, Chen Z-M, et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. *Br Med J* 1998;317: 1411–22.
5. Niu S-R, Yang G-H, Chen Z-M, et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. *Br Med J* 1998;317: 1423–24.
6. Robertson TL, Kato H, Gordon T, Kagan A, Rhoads GG, Land CE, Worth RM, Belsky JL, Dock DS, Miyanishi M, Kawamoto S. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. *Am J Cardiol*. 1977;39(2):244-9. PubMed PMID: 835483.
7. Lawlor DA, Song YM, Sung J, Ebrahim S, Smith GD. The association of smoking and cardiovascular disease in a population with low cholesterol levels: a study of 648,346 men from the Korean national health system prospective cohort study. *Stroke*.

1
2
3
4 2008;39(3):760-7. doi: 10.1161/STROKEAHA.107.494823. Epub 2008 Jan 31.

5
6 PubMed PMID: 18239177.

7
8
9
10 8. Hozawa A, Okamura T, Kadowaki T, Murakami Y, Nakamura K, Hayakawa T, Kita
11 Y, Nakamura Y, Okayama A; Hirotsugu Ueshima for NIPPON DATA80 Research
12 group. Is weak association between cigarette smoking and cardiovascular disease
13 mortality observed in Japan explained by low total cholesterol? NIPPON DATA80. *Int*
14 *J Epidemiol.* 2007 Oct;36(5):1060-7. Epub 2007 Sep 10. PubMed PMID: 17846054.
15
16
17
18

19
20
21
22 9. Nakamura K, Barzi F, Huxley R, Lam TH, Suh I, Woo J, Kim HC, Feigin VL, Gu D,
23 Woodward M; Asia Pacific Cohort Studies Collaboration. Does cigarette smoking
24 exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the
25 risk of cardiovascular diseases? *Heart.* 2009;95(11):909-16. doi:
26 10.1136/hrt.2008.147066. Epub 2009 Feb 5. PubMed PMID: 19196734.
27
28
29
30
31
32

33
34 10. Jee SH, Suh I, Kim IS, Appel LJ. Smoking and atherosclerotic cardiovascular
35 disease in men with low levels of serum cholesterol: the Korea Medical Insurance
36 Corporation Study. *JAMA.* 1999;282(22):2149-55.
37
38
39
40

41
42 11. Jee SH, Park J, Jo I, Lee J, Yun S, Yun JE, Jang Y. Smoking and atherosclerotic
43 cardiovascular disease in women with lower levels of serum cholesterol.
44 *Atherosclerosis.* 2007;190(2):306-12. Epub 2006 May 4.
45
46
47
48

49
50 12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones
51 DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and
52 Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and
53 Treatment of High Blood Pressure; National High Blood Pressure Education Program
54
55
56
57
58

1
2
3
4 Coordinating Committee. The Seventh Report of the Joint National Committee on
5 Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7
6 report. *JAMA*. 2003;289(19):2560-72. Epub 2003 May 14. Erratum in: *JAMA*. 2003 Jul
7 9;290(2):197. PubMed PMID: 12748199.
8
9
10
11
12

13
14 13. The National Cholesterol Education Program. Report of the Expert Panel on Blood
15 Cholesterol Levels in Children and Adolescents. NIH Publication No. 91-2732.
16 Bethesda, MD; 1994.
17
18
19
20
21

22
23 14. National Diabetes Data Group. Report of the Expert Committee on the Diagnostic
24 Classification of Diabetes. *Diabetes Care*. 1997;20(7):1183-97.
25
26

27
28 15. Kimm H, Yun JE, Lee SH, et al. Validity of the diagnosis of acute myocardial
29 infarction in Korean national medical health insurance claims data: the Korean Heart
30 Study (1). *Korean Circ J* 2012;42:10-15.
31
32
33

34
35 16. Kim HY. Validity of the diagnosis of acute myocardial infarction in Korean
36 national medical health insurance claims data: the Korean Heart Study [Master thesis].
37 Yonsei University, Seoul, Korea, June 2013.
38
39
40
41

42
43 17. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1: The analysis
44 of case-control studies. Lyon, France: IARC Scientific Publication No. 32, pp. 146-50.
45
46
47

48
49 18. Levin ML. The occurrence of lung cancer in man. *Acta Intern Cancer* 1953;19:531.
50

51
52 19. Thut AB, Blizzard L, Schmidt MD, Luc PH, Granger RH, Dwyer T. The association
53 between smoking and hypertension in a population-based sample of Vietnamese men. *J*
54 *Hypertens*. 2010; 28: 245 - 50.
55
56
57

- 1
2
3
4 20. Kim BJ, Seo DC, Kim BS, Kang JH. Relationship between cotinine-verified
5 smoking status and incidence of hypertension in 74,743 Korean adults. *Circ J*. 2018 Feb
6
7 28. doi: 10.1253/circj.CJ-17-1188. [Epub ahead of print].
8
9
10
11 21. Morotti E, Battaglia B, Fabbri R, Paradisi R, Venturoli S, Battaglia C. Cigarette
12 smoking and cardiovascular risk in young women with polycystic ovary syndrome. *Int*
13 *J Fertil Steril*. 2014;7(4):301-12. Epub 2013 Dec 22.
14
15
16
17 22. Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the
18 general population in Japan. *J Hypertens* 1990;8(Suppl 5):S9–S15.
19
20
21 23. Fujishima M, Kiyohara Y, Ueda K, Hasuo Y, Kato I, Iwamoto H. Smoking as
22 cardiovascular risk factor in low cholesterol population: the Hisayama Study. *Clin Exp*
23 *Hypertens A*. 1992;14(1-2):99-108.
24
25
26 24. Gordon T, Garcia-Palmier MR, Kagan A, Kannel WB, Schiffman J. Differences in
27 coronary heart disease in Framingham, Honolulu and Puerto Rico. *J Chronic Dis*.
28 1974;27:329–44.
29
30
31 25. Thun, M. J., Day-Lally, C., Myers, D. G., Calle, E. E., Flanders, W., Zhu, B., ... &
32 Heath, C. W. (1982). Trends in tobacco smoking and mortality from cigarette use in
33 Cancer Prevention Studies I (1959 through 1965) and II (1982 through 1988). National
34 Cancer institute, smoking and tobacco control, monograph, 8.
35
36
37 26. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking
38 cessation in relation to mortality in women. *JAMA*. 2008;299(17):2037-47.
39
40
41
42 27. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 cessation: myocardial infarction and stroke. *Circulation*. 1997;96(4):1089-96.
5
6

7 28. Bernaards CM1, Twisk JW, Snel J, van Mechelen W, Kemper HC. In a prospective
8 study in young people, associations between changes in smoking behavior and risk
9 factors for cardiovascular disease were complex. *J Clin Epidemiol*. 2005
10 Nov;58(11):1165-71.
11
12
13
14
15

16 29. Murtaugh KH, Borde-Perry WC, Campbell KL, Gidding SS, Falkner B. Obesity,
17 smoking, and multiple cardiovascular risk factors in young adult African Americans.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

30. West HW, Juonala M, Gall SL, Kähönen M, Laitinen T, Taittonen L, Viikari JS,
aitakari OT, Magnussen CG. Exposure to parental smoking in childhood is associated
with increased risk of carotid atherosclerotic plaque in adulthood: the Cardiovascular
Risk in Young Finns Study. *Circulation*. 2015 Apr 7;131(14):1239-46. doi:
10.1161/CIRCULATIONAHA.114.013485. Epub 2015 Mar 23.

31. Roy MP, Steptoe A, Kirschbaum C. Association between smoking status and
cardiovascular and cortisol stress responsivity in healthy young men. *Int J Behav Med*.
1994;1(3):264-83.

Figure legends

Figure 1. Timeline for data collection in the Korean Life Course Health Study

1
2
3
4
5
6
7 Figure 2. Survival of atherosclerotic cardiovascular disease event by smoking history in
8 Korean young adult men, 1992-2015
9
10

11
12
13
14
15 Figure 3. Hazard ratios with 95% confidence intervals for from ischemic heart disease,
16 and stroke by cigarette per day and duration of smoking
17
18
19

20
21
22
23 Figure 4. Hazard ratios with 95% confidence intervals for ischemic heart disease and
24 stroke by total cholesterol groups of smokers compared with nonsmokers: Each group
25 of total cholesterol levels are as follows: first, 149 mg/dl; second, 150-169 mg/dL; third,
26 170-194 mg/dL; fourth, ≥ 195 mg/dL. The reference group is non-smokers in each
27 quartile of total cholesterol.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline Characteristics of the Korean Life Course Health Study, 1992-1994, According to Smoking Status*

Characteristic	Nonsmokers (n=24,950)	Ex-smokers (n=15,126)	No. of cigarettes per day among current smokers			P for Trend†‡
			1-9 (n=22,642)	10-19 (n=35,690)	≥20 (n=20,123)	
Age, year	26.6 (2.1)	26.9 (1.9)	26.6 (2.0)	26.8 (1.9)	26.8 (1.9)	0.1622
Systolic Blood Pressure, mmHg	120.4 (11.6)	120.0 (11.8)	119.8 (11.6)	120.1 (11.6)	120.3 (11.6)	0.2558
Diastolic Blood Pressure mmHg	78.0 (9.0)	77.7 (9.1)	77.5 (9.0)	77.8 (9.0)	78.0 (9.0)	0.1122
Total cholesterol, mg/dL	173.4 (32.9)	173.4 (32.6)	172.9 (33.1)	174.5 (33.4)	177.2 (34.4)	0.9543
Body mass index, kg/m ²	22.3 (2.4)	22.4 (2.4)	22.3 (2.4)	22.5 (2.5)	22.9 (2.6)	0.0056
Fasting serum glucose, mg/dL	86.7 (13.3)	86.6 (13.5)	86.2 (14.1)	86.4 (14.1)	86.6 (15.3)	0.4821
Alcohol consumption, g per day	7.3 (17.7)	9.7 (19.7)	12.2 (22.6)	14.5 (25.1)	20.4 (36.1)	<.0001
Conditions, %						
Hypertension†	15.7	15.1	14.5	15.6	15.7	0.7987
Hypercholesterolemia‡	3.4	3.3	3.3	3.9	4.7	0.0743
Diabetes§	0.7	0.8	0.9	0.9	1.0	0.0060
Alcohol use	61.2	81.3	88.2	88.3	86.9	0.1035
Physical activity	24.9	26.8	22.9	17.5	13.0	<.0001

*Data are expressed as means (SD) unless otherwise indicated; †Systolic blood pressure of at least 140 mmHg and/or diastolic blood pressure of at least

1
2
3 90 mmHg; ‡Total cholesterol level of at least 6.21 mmol/L (240 mg/dL); § Fasting serum glucose value of at least 6.99 mmol/L (126 mg/L); || Consumption
4 of Soju which is a colorless distilled beverage of Korean origin; ¶¶Testing for trend across nonsmokers and current smokers; ex-smokers were excluded.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Table 2. Risk of Morbidity from Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men in the Korean Life Course Health Study, 1992-2015*

Variables and Categories	Ischemic Heart Disease		Cerebrovascular Disease		Atherosclerotic Cardiovascular Disease	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age (5-year age group)	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.3 (1.2 – 1.4)	<.0001
Cigarette smoking						
Ex-smoker	1.0 (0.9 – 1.2)	0.8567	1.1 (0.9 – 1.3)	0.5008	1.1 (1.0 – 1.2)	0.1406
Current smoker	1.5 (1.3 – 1.6)	<.0001	1.4 (1.2 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
Blood Pressure†						
High normal	1.2 (1.1 – 1.4)	<.0001	1.2 (1.0 – 1.3)	0.0152	1.2 (1.1 – 1.3)	<.0001
Stage 1 hypertension	1.6 (1.4 – 1.8)	<.0001	1.7 (1.5 – 2.0)	<.0001	1.7 (1.5 – 1.8)	<.0001
Stage 2 hypertension	2.0 (1.6 – 2.5)	<.0001	3.2 (2.5 – 4.0)	<.0001	2.9 (2.5 – 3.3)	<.0001
Total cholesterol‡						
Borderline-high cholesterol	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.6)	<.0001	1.4 (1.3 – 1.5)	<.0001
High cholesterol	2.5 (2.1 – 2.8)	<.0001	1.7 (1.4 – 2.1)	<.0001	2.1 (1.8 – 2.3)	<.0001
Fasting blood sugar§						
Diabetes	1.3 (0.9 – 1.9)	0.1375	1.6 (1.1 – 2.3)	0.0222	1.5 (1.2 – 1.9)	0.0008
Physical activity						
No exercise	1.1 (1.0 – 1.3)	0.0122	1.1 (1.0 – 1.3)	0.2156	1.1 (1.0 – 1.3)	0.0075

*Hazard ratio (HRs) and 95% confidence intervals (CIs) from multivariable Cox proportional hazards models. †The reference category is normal (systolic

1
2
3 blood pressure<140 mmHg and diastolic blood pressure<90mm Hg). ‡ The reference category is desirable (serum cholesterol level, < 5.17 mmol/L [200
4 mg/dL]). §The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46


For peer review only

Table 3. Population Attributable Risks (PARs) and 95% Confidence Intervals (CIs) From Smoking and Other Risk Factors of Ischemic Heart Disease, Cerebrovascular Disease, and Atherosclerotic Cardiovascular Disease in Korean Men: The Korean Life Course Health Study

Variables and Categories	Prevalence %	Ischemic Heart Disease PAR (95% CI)	Cerebrovascular Disease PAR (95% CI)	Atherosclerotic Cardiovascular Disease PAR (95% CI)
Smoking				
Current smoker	66.2	24.9 (16.6 – 28.4)	20.9 (11.7 -28.4)	20.9 (16.5 – 24.9)
Blood Pressure*				
Hypertension	22.0	8.1 (6.2 – 9.9)	13.3 (9.9 – 14.9)	9.9 (9.9 – 11.7)
Total cholesterol†				
Borderline	16.6	6.2 (4.7 – 9.1)	6.2 (4.7 – 7.7)	6.2 (4.7 – 7.6)
High	3.8	5.4 (4.0 – 6.4)	4.0 (2.9 – 4.7)	4.0 (2.9 – 4.7)
Fasting blood sugar‡				
Diabetes	0.9	0.3 (-0.9 – 0.8)	0.5 (0.08 – 1.1)	0.4 (0.2 – 0.8)
Physical activity				
No exercise	0.8	7.4 (0 – 19.3)	7.4 (0 – 19.3)	7.4 (0 – 19.3)

*The reference category is normal (systolic blood pressure < 140 mmHg and diastolic blood pressure < 90mm Hg). †The reference category is desirable (serum cholesterol level < 5.17 mmol/L [200 mg/dL]). ‡ The reference category is a fasting serum glucose level of less than 6.99 mmol/L (126 mg/dL).

Figure 1



69x33mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 2


254x190mm (300 x 300 DPI)

Figure 3.


A. Ischemic Heart Disease




B. Ischemic Heart Disease




C. Stroke




D. Stroke



E. ASCVD




F. ASCVD



46x53mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4.



46x94mm (300 x 300 DPI)

Title: *smoking is the first leading cause of cardiovascular disease in Young Men.*

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	①	(a) Indicate the study's design with a commonly used term in the title or the abstract <i>Page 3</i> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <i>page 3</i>
Introduction		
Background/rationale	②	Explain the scientific background and rationale for the investigation being reported <i>page 5</i>
Objectives	③	State specific objectives, including any prespecified hypotheses <i>page 6, para 1.</i>
Methods		
Study design	④	Present key elements of study design early in the paper <i>Page 6, para 2</i>
Setting	⑤	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <i>page 6-7.</i>
Participants	⑥	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>page 6, page 8</i> (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	⑦	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <i>page 7, para 3, page 8</i>
Data sources/ measurement	⑧*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <i>page 6, page 7</i>
Bias	⑨	Describe any efforts to address potential sources of bias <i>page 14.</i>
Study size	⑩	Explain how the study size was arrived at <i>page 7</i>
Quantitative variables	⑪	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <i>page 8</i>
Statistical methods	⑫	(a) Describe all statistical methods, including those used to control for confounding <i>page 9</i> (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed <i>page 8</i> (e) Describe any sensitivity analyses <i>page 9-10</i>
Results		
Participants	⑬*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <i>page 10</i> (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram <i>page 7. (Figure 1)</i>
Descriptive data	⑭*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <i>page 10</i> (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) <i>page 10 (23 years of follow-up)</i>
Outcome data	⑮*	Report numbers of outcome events or summary measures over time <i>page 10.</i>
Main results	⑯	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <i>page 10, para 1 (Table 2)</i> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

1	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	page 11 (Figure 4)
2	Discussion			
3	Key results	18	Summarise key results with reference to study objectives	page 12 para 2
4	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	page 14, para 2.
5	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	page 14
6	Generalisability	21	Discuss the generalisability (external validity) of the study results	page 14
7	Other information			
8	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	page 15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.